ISRAEL
Inspired by innovation

at Medica 2017
Düsseldorf / November 13–16 / Hall 16, Stand G40

Meeting Global Healthcare Challenges
Why Israel?

DIVERSITY is the backbone of Israel’s Medical Device Industry:
Diverse Companies – Diverse Technological Implementation – Diverse Medical Applications.

By the end of the 1990s, Israel was home to more than 200 life science companies. With steady growth over the last decade (some 40 new companies formed each year), Israel has introduced creativity and innovation into the field; today there are over 1300 active life science companies.

In a relatively short period of time, an impressive 40 percent of these companies are already generating revenues. Israel’s entrepreneurial ecosystem creates opportunities for start-ups to become advanced, commercially viable and promising businesses. As proof of the industry’s development, 2014 life science exports reached $8.5 billion, growing steadily since 2008; while a rich pipeline of seed companies promises to perpetuate current growth.

The Largest Sector is Medical Devices and HealthCare IT Technologies (more than 65 percent of companies). In the medical device arena, Israeli scientists and engineers have integrated advanced technologies in electronics, communications and electrooptics to develop world-class innovations in Digital Imaging, Medical Lasers, Telemedicine, Early Diagnostic and Smart Surgical equipment and more. More than 500 medical device exporters engaged in a variety of medical applications such as Cardiovascular and Peripheral Vascular, Neurology and Degenerative Diseases, Emergency Medicine, Intensive Care and Rehabilitation, Respiratory and Airway Management, Oncology, Women’s Health, Orthopedics and Sport Medicine, Gastrointestinal, Infection Control, Ophthalmology, Pain and Wound Management, Oral and Dental, Dermatology and Aesthetics.

There is no other country in the world with such a concentration of life science companies. Companies rooted in top international academic and research institutions; staffed by highly educated and skilled teams; operating within an entrepreneurial and audacious climate, to offer a variety of innovative medical solutions and technologies that answer today’s healthcare challenges: to lower overall healthcare costs and meet the world’s evolving needs of aging populations while creating significant investor value.
Israel Inspired by Innovation at MEDICA 2017

The Israel Export & International Cooperation Institute, supported by member firms, private sector bodies and the government of Israel, advances business relationships between Israeli exporters and overseas businesses and organizations. By providing a wide range of export-oriented services to Israeli companies and complementary services to the international business community, the Institute helps build successful joint ventures, strategic alliances and trade partnerships.

The IEICI’s Life Science Department is the leader in business matching between the more than 1,300 companies in the Israeli life science industry and worldwide business partners at all levels. It has a proven ability to identify and match suitable potential business partners, organize one-on-one business meetings, and is a focal point for contacts with the government as well as with industry.

The IEICI is the major organizer of Israeli companies’ participation at MEDICA 2017. Discover Israeli Life Science Industry with IEICI.

Angela W. Rabinovich, Director, Life Science Department
The Israel Export & International Cooperation Institute
Tel: +972 3 514 2891, E-mail: angela@export.gov.il

Tomer Epstein, Manager, Medical Device & HealthCare IT
The Israel Export & International Cooperation Institute
Tel: +972 3 514 2938, E-mail: tomere@export.gov.il

www.export.gov.il
The Foreign Trade Administration at MEDICA 2017

The Foreign Trade Administration (FTA) at the Israeli Ministry of Economy and Industry manages and supports Israel’s international trade and trade policy. Through our headquarters in Jerusalem together with over 40 economic and trade missions in key financial centers throughout the world, the FTA promotes Israel’s economy worldwide. Israel’s economic and trade missions are at the forefront of the Israeli government’s efforts to boost our industries in foreign markets. Our team of highly experienced economic representatives and business consultants provide a wide range of services to Israeli companies and to the international business community.

The FTA is divided into three main divisions, each promoting the Israeli economy in distinct and significant ways:

- The Trade Promotion Division – works to ensure the continued development of Israel’s exports.
- The Trade Policy and International Agreements Division – responsible for Israel’s free trade agreements, maintaining and developing inter-governmental relations and addressing regulatory barriers that affect Israeli industry.
- The International Projects and Financing Division – offers different programs that support Israeli companies in their business operations abroad.

At MEDICA 2017, for the 10th consecutive year our Economic and Trade Missions around the world will continue to work on connecting the international business community with Israel’s innovative Medical Devices Industry, as it has done in previous years with great success.

For contact details of the FTA’s Economic Missions abroad, please see page 75

Joseph Akerman, Project Manager – MEDICA 2017
Foreign Trade Administration, Ministry of Economy and Industry
+972 2 666 2776, josepha@economy.gov.il

www.itrade.gov.il
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Category &amp; Sub-Category</th>
<th>Therapeutic Areas(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allium</td>
<td>Medical Devices</td>
<td>Urology, Gynecology, Gastrointestinal</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>Disposable &amp; Implantable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B-Cure Laser</td>
<td>Medical Devices</td>
<td>Diabetics, Oral &amp; Dental Care, Inflammation, Orthopedic, Wound Management, Veterinary, Rehabilitation</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRH Medical</td>
<td>Medical Devices</td>
<td>Wound Management, Diabetics</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biobeat</td>
<td>Medical Devices</td>
<td>Cardiovascular</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Telemedicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biolight Medical Devices</td>
<td>Medical Devices</td>
<td>Allergy, ENT - Ear, Nose &amp; Throat</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biop Medical</td>
<td>Medical Devices</td>
<td>Oncology, Gynecology, Women's Health</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Diagnostic &amp; Monitoring</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Endoscope &amp; Accessories</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Imaging</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HealthCare IT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bo&amp;Bo</td>
<td>Medical Devices</td>
<td>Orthopedic, Rehabilitation, Neurology &amp; Degenerative Disease</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiacx Medical</td>
<td>Medical Devices</td>
<td>Cardiovascular, EMS - Emergency Medicine Services</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chaban Medical Ltd.</td>
<td>Medical Devices</td>
<td>Respiratory, Dermatology &amp; Aesthetics</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cnoga Medical</td>
<td>Medical Devices</td>
<td>Diabetics, Endocrinology, Cardiovascular, EMS - Emergency Medicine Services, General Health, Pulmonary, Primary Care, Respiratory, Women's Health</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>Diagnostic &amp; Monitoring</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Telemedicine</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Table of Contents by Companies

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Category &amp; Sub-Category</th>
<th>Therapeutic Areas(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Core Scientific Creations</td>
<td>Medical Devices</td>
<td>Wound Management&lt;br&gt;EMS - Emergency Medicine Services&lt;br&gt;General Surgery&lt;br&gt;Cardiovascular&lt;br&gt;Oncology&lt;br&gt;Orthopedic&lt;br&gt;Nephrology&lt;br&gt;Oral &amp; Dental Care&lt;br&gt;Obstetrics&lt;br&gt;Gynecology&lt;br&gt;ENT - Ear, Nose &amp; Throat&lt;br&gt;Urology&lt;br&gt;Peripheral Vascular</td>
<td>30</td>
</tr>
<tr>
<td>DPE Medical</td>
<td>Medical Devices</td>
<td>Rehabilitation&lt;br&gt;Physiotherapy&lt;br&gt;Cardiovascular&lt;br&gt;Neurology &amp; Degenerative Disease&lt;br&gt;Neuroscience&lt;br&gt;Orthopedic&lt;br&gt;Pediatrics&lt;br&gt;Pulmonary&lt;br&gt;General Health</td>
<td>31</td>
</tr>
<tr>
<td>Dr. Sagie Bedwetting clinics</td>
<td>Healthcare IT</td>
<td>Pediatrics</td>
<td>32</td>
</tr>
<tr>
<td>DYN R&amp;D</td>
<td>Medical Devices</td>
<td>Gynecology&lt;br&gt;Women's Health&lt;br&gt;Dermatology &amp; Aesthetics</td>
<td>33</td>
</tr>
<tr>
<td>EarlySense</td>
<td>Medical Devices</td>
<td>Cardiovascular&lt;br&gt;Infection Control&lt;br&gt;Internal Medicine&lt;br&gt;Oncology&lt;br&gt;Orthopedic&lt;br&gt;Rehabilitation&lt;br&gt;Respiratory&lt;br&gt;Psychiatry&lt;br&gt;Pulmonary</td>
<td>34</td>
</tr>
</tbody>
</table>
# Table of Contents by Companies

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Category &amp; Sub-Category</th>
<th>Therapeutic Areas(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equatel</td>
<td><strong>Medical Devices</strong></td>
<td>General Health</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Telemedicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estar Technologies</td>
<td><strong>Medical devices</strong></td>
<td>Dermatology &amp; Aesthetics</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>Orthopedic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biotechnology</td>
<td>Oral &amp; Dental Care</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biomaterials &amp; Plasma Products</td>
<td>Veterinary</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tissue Engineering &amp; Cell Therapy</td>
<td>Wound Management</td>
<td></td>
</tr>
<tr>
<td>Exalenz Bioscience</td>
<td><strong>Medical devices</strong></td>
<td>Gastrointestinal</td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>Diagnostic &amp; Monitoring</td>
<td>General Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Primary Care</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Primary Care</td>
<td></td>
</tr>
<tr>
<td>Flight Medical</td>
<td><strong>Medical devices</strong></td>
<td>Respiratory</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>Primary Care</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pulmonary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>EMS - Emergency Medicine Services</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ICU - Intensive Care Unit</td>
<td></td>
</tr>
<tr>
<td>GlucoMe</td>
<td><strong>Medical Devices</strong></td>
<td>Endocrinology</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>Diagnostic &amp; Monitoring</td>
<td>Diabetics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Telemmedicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gordian Surgical</td>
<td><strong>Medical Devices</strong></td>
<td>Obesity</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>General Surgery</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gynecology</td>
<td></td>
</tr>
<tr>
<td>Guide In Medical</td>
<td><strong>Medical Devices</strong></td>
<td>Respiratory</td>
<td>41</td>
</tr>
<tr>
<td></td>
<td>Disposable &amp; Implantable</td>
<td>EMS - Emergency Medicine Services</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Endoscope &amp; Accessories</td>
<td>ICU - Intensive Care Unit</td>
<td></td>
</tr>
<tr>
<td>HealthWatch</td>
<td><strong>Medical Devices</strong></td>
<td>Cardiovascular</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>Diagnostic &amp; Monitoring</td>
<td>Respiratory</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Telemmedicine</td>
<td>General Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Healthcare IT</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Table of Contents by Companies

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Category &amp; Sub-Category</th>
<th>Therapeutic Areas(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hip Hope Technologies</td>
<td><strong>Medical Devices</strong></td>
<td>Orthopedic</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>Diagnostic &amp; Monitoring</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>Rehabilitation</td>
<td></td>
</tr>
<tr>
<td>Hygimed by Maabarot &amp; Ashylon</td>
<td><strong>Medical Devices</strong></td>
<td>General Health</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>Disposable &amp; Implantable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IceCure Medical</td>
<td><strong>Medical Devices</strong></td>
<td>Women's Health</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>MIS - Minimally Invasive System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inovytec Medical Solutions</td>
<td><strong>Medical Devices</strong></td>
<td>EMS - Emergency Medicine Services</td>
<td>46</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>Cardiovascular</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Telemedicine</td>
<td>Respiratory</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Healthcare IT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lumenis</td>
<td><strong>Medical Devices</strong></td>
<td>ENT - Ear, Nose &amp; Throat</td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>Gynecology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MIS - Minimally Invasive System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medasense Biometrics</td>
<td><strong>Medical Devices</strong></td>
<td>Pain Management</td>
<td>48</td>
</tr>
<tr>
<td></td>
<td>Diagnostic &amp; Monitoring</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medisim</td>
<td><strong>Medical Devices</strong></td>
<td>General Health</td>
<td>49</td>
</tr>
<tr>
<td></td>
<td>Diagnostic &amp; Monitoring</td>
<td>Intensive Care</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>EMS - Emergency Medicine Services</td>
<td></td>
</tr>
<tr>
<td>Medispec</td>
<td><strong>Medical Devices</strong></td>
<td>Cardiovascular</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>Nephrology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Orthopedic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Veterinary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wound Management</td>
<td></td>
</tr>
<tr>
<td>MediTouch</td>
<td><strong>Medical Devices</strong></td>
<td>Neurology &amp; Degenerative Disease</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>Neuroscience</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Orthopedic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pediatrics</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rehabilitation</td>
<td></td>
</tr>
</tbody>
</table>
# Table of Contents by Companies

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Category &amp; Sub-Category</th>
<th>Therapeutic Areas(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mennen Medical &amp; MTRE</td>
<td>Medical Devices</td>
<td>ICU - Intensive Care Unit</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cardiovascular</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pediatrics</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neuroscience</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>General Surgery</td>
<td></td>
</tr>
<tr>
<td>Meditrac</td>
<td>Medical Devices</td>
<td>Orthopedic</td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mizra Medical</td>
<td>Medical Devices</td>
<td>General Health</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>Urology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Disposable &amp; Implantable</td>
<td>Orthopedic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>OTC - Over the Counter</td>
<td>Pediatrics</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ENT - Ear, Nose &amp; Throat</td>
<td></td>
</tr>
<tr>
<td>NanoVibronix</td>
<td>Medical Devices</td>
<td>Infection Control</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>Urology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wound Management</td>
<td></td>
</tr>
<tr>
<td>neoLaser</td>
<td>Medical Devices</td>
<td>General Surgery</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>Peripheral Vascular</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Orthopedic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neuroscience</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ENT - Ear, Nose &amp; Throat</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Women's Health</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oncology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dermatology &amp; Aesthetics</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Veterinary</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oral &amp; Dental Care</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pediatrics</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pulmonary</td>
<td></td>
</tr>
<tr>
<td>Noam Urim</td>
<td>Medical Devices</td>
<td>Infection Control</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>Disposable &amp; Implantable</td>
<td>Primary Care</td>
<td></td>
</tr>
<tr>
<td></td>
<td>OTC - Over the Counter</td>
<td>General Health</td>
<td></td>
</tr>
<tr>
<td>Nuvo Group</td>
<td>Medical Devices</td>
<td>Gynecology</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td>Diagnostic &amp; Monitoring</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Healthcare IT</td>
<td>Obstetrics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Decision Support System</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Table of Contents by Companies

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Category &amp; Sub-Category</th>
<th>Therapeutic Areas(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCON Medical</td>
<td>Medical Devices</td>
<td>Women's Health</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>Disposable &amp; Implantable</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drug delivery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peak Medical</td>
<td>Medical Devices</td>
<td>ICU - Intensive Care Unit</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharma Sept</td>
<td>Medical Devices</td>
<td>ENT - Ear, Nose and Throat</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td>Disposable &amp; Implantable</td>
<td>General Surgery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td>Neurology &amp; Degenerative Disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Industrial use / OEM</td>
<td>Orthopedic</td>
<td></td>
</tr>
<tr>
<td>Playwork</td>
<td>Medical Devices</td>
<td>Rehabilitation</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td>Training</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Healthcare IT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polycart Medical</td>
<td>Medical Devices</td>
<td>General Health</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Qinflow</td>
<td>Medical Devices</td>
<td>EMS - Emergency Medicine Services</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>Veterinary</td>
<td></td>
</tr>
<tr>
<td>Salute Rehab</td>
<td>Medical Devices</td>
<td>Rehabilitation</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>Pediatrics</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cardiovascular</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neurology &amp; Degenerative Disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Orthopedic</td>
<td></td>
</tr>
<tr>
<td>Shekel Scales Ltd.</td>
<td>Medical Devices</td>
<td>General Health</td>
<td>66</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Healthcare IT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Telemedicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EHR</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SW and HW</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hospital Units/Clinics</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Industrial use / OEM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Table of Contents by Companies

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Category &amp; Sub-Category</th>
<th>Therapeutic Areas(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SION Medical Ltd.</td>
<td><strong>Medical Devices</strong></td>
<td>cardiovascular</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td>Disposable &amp; Implantable</td>
<td>Infection Control</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ophthalmology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Orthopedic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wound Management</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gynecology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urology</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Veterinary</td>
<td></td>
</tr>
<tr>
<td>Synergo by Medical Enterprises Group</td>
<td><strong>Medical Devices</strong></td>
<td>Urology</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>Oncology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MIS - Minimally Invasive System</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drug delivery</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nanotechnology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drug Targeting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TavTech</td>
<td><strong>Medical Devices</strong></td>
<td></td>
<td>69</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Disposable &amp; Implantable</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Endoscope &amp; Accessories</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MIS - Minimally Invasive System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Via Surgical</td>
<td><strong>Medical Devices</strong></td>
<td>General Surgery</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>MIS - Minimally Invasive System</td>
<td>Obesity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Disposable &amp; Implantable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viasonix</td>
<td><strong>Medical Devices</strong></td>
<td>Peripheral Vascular</td>
<td>71</td>
</tr>
<tr>
<td></td>
<td>Medical Equipment</td>
<td>Neurology &amp; Degenerative Disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diagnostic &amp; Monitoring</td>
<td>Neuroscience</td>
<td></td>
</tr>
<tr>
<td>Virility Medical</td>
<td><strong>Medical Devices</strong></td>
<td>Urology</td>
<td>72</td>
</tr>
<tr>
<td></td>
<td>Disposable &amp; Implantable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitalerter</td>
<td><strong>Medical Devices</strong></td>
<td>General Health</td>
<td>73</td>
</tr>
<tr>
<td></td>
<td>Monitoring</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Healthcare IT</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diagnostic &amp; Monitoring</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Table of Contents by Categories

<table>
<thead>
<tr>
<th>Medical Devices</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diagnostic &amp; Monitoring</strong></td>
<td></td>
</tr>
<tr>
<td>Biop Medical</td>
<td>25</td>
</tr>
<tr>
<td>Cnoga Medical</td>
<td>29</td>
</tr>
<tr>
<td>DPE Medical</td>
<td>31</td>
</tr>
<tr>
<td>EarlySense</td>
<td>34</td>
</tr>
<tr>
<td>Exalenz Bioscience</td>
<td>37</td>
</tr>
<tr>
<td>GlucoMe</td>
<td>39</td>
</tr>
<tr>
<td>HealthWatch</td>
<td>42</td>
</tr>
<tr>
<td>Hip Hope Technologies</td>
<td>43</td>
</tr>
<tr>
<td>Medasense Biometrics</td>
<td>48</td>
</tr>
<tr>
<td>Medisim</td>
<td>49</td>
</tr>
<tr>
<td>Mennen Medical &amp; MTRE</td>
<td>52</td>
</tr>
<tr>
<td>Nuvo Group</td>
<td>58</td>
</tr>
<tr>
<td>Viasonix</td>
<td>71</td>
</tr>
<tr>
<td>Vitalerter</td>
<td>73</td>
</tr>
<tr>
<td><strong>Disposable &amp; Implantable</strong></td>
<td></td>
</tr>
<tr>
<td>Allium</td>
<td>20</td>
</tr>
<tr>
<td>Core Scientific Creations</td>
<td>30</td>
</tr>
<tr>
<td>Hygimed by Maabarot &amp; Ashylon</td>
<td>44</td>
</tr>
<tr>
<td>Gordian Surgical</td>
<td>40</td>
</tr>
<tr>
<td>Guide In Medical</td>
<td>41</td>
</tr>
<tr>
<td>Mizra Medical</td>
<td>54</td>
</tr>
<tr>
<td>Noam Urim</td>
<td>57</td>
</tr>
<tr>
<td>OCON Medical</td>
<td>59</td>
</tr>
<tr>
<td>Pharma Sept</td>
<td>61</td>
</tr>
<tr>
<td>Sion Medical</td>
<td>67</td>
</tr>
<tr>
<td>TavTech</td>
<td>69</td>
</tr>
<tr>
<td>Via Surgical</td>
<td>70</td>
</tr>
<tr>
<td>Virility Medical</td>
<td>72</td>
</tr>
<tr>
<td><strong>Endoscope &amp; Accessories</strong></td>
<td></td>
</tr>
<tr>
<td>Biop Medical</td>
<td>25</td>
</tr>
<tr>
<td>Guide In Medical</td>
<td>41</td>
</tr>
<tr>
<td>TavTech</td>
<td>69</td>
</tr>
</tbody>
</table>
## Table of Contents by Categories

### Medical Devices

<table>
<thead>
<tr>
<th>Category</th>
<th>Companies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medical Equipment</strong></td>
<td>BRH Medical</td>
</tr>
<tr>
<td></td>
<td>Cardiacx Medical</td>
</tr>
<tr>
<td></td>
<td>Chaban Medical</td>
</tr>
<tr>
<td></td>
<td>DPE Medical</td>
</tr>
<tr>
<td></td>
<td>DYN R&amp;D</td>
</tr>
<tr>
<td></td>
<td>Estar Technologies</td>
</tr>
<tr>
<td></td>
<td>Flight Medical</td>
</tr>
<tr>
<td></td>
<td>Gordian Surgical</td>
</tr>
<tr>
<td></td>
<td>Inovytec Medical Solutions</td>
</tr>
<tr>
<td></td>
<td>Lumenis</td>
</tr>
<tr>
<td></td>
<td>Medispec</td>
</tr>
<tr>
<td></td>
<td>MediTouch</td>
</tr>
<tr>
<td></td>
<td>Meditrac</td>
</tr>
<tr>
<td></td>
<td>Mizra Medical</td>
</tr>
<tr>
<td></td>
<td>NanoVibronix</td>
</tr>
<tr>
<td></td>
<td>neoLaser</td>
</tr>
<tr>
<td></td>
<td>Peak Medical</td>
</tr>
<tr>
<td></td>
<td>Polycart Medical</td>
</tr>
<tr>
<td></td>
<td>Qinflow</td>
</tr>
<tr>
<td></td>
<td>Salute Rehab</td>
</tr>
<tr>
<td></td>
<td>Shekel Scales</td>
</tr>
<tr>
<td></td>
<td>Synergo by Medical Enterprises Group</td>
</tr>
<tr>
<td></td>
<td>TavTech</td>
</tr>
<tr>
<td></td>
<td>Viasonic</td>
</tr>
<tr>
<td><strong>MIS - Minimally Invasive System</strong></td>
<td>Gordian Surgical</td>
</tr>
<tr>
<td></td>
<td>IceCure Medical</td>
</tr>
<tr>
<td></td>
<td>Lumenis</td>
</tr>
<tr>
<td></td>
<td>Synergo by Medical Enterprises Group</td>
</tr>
<tr>
<td></td>
<td>TavTech</td>
</tr>
<tr>
<td></td>
<td>Via Surgical</td>
</tr>
<tr>
<td><strong>Telemedicine</strong></td>
<td>Biobeat</td>
</tr>
<tr>
<td></td>
<td>Cnoga Medical</td>
</tr>
<tr>
<td></td>
<td>DPE Medical</td>
</tr>
<tr>
<td></td>
<td>EarlySense</td>
</tr>
<tr>
<td></td>
<td>Equatel</td>
</tr>
<tr>
<td></td>
<td>GlucoMe</td>
</tr>
<tr>
<td></td>
<td>HealthWatch</td>
</tr>
<tr>
<td></td>
<td>Inovytec Medical Solutions</td>
</tr>
<tr>
<td></td>
<td>Shekel Scales</td>
</tr>
</tbody>
</table>
# Table of Contents by Categories

<table>
<thead>
<tr>
<th>Medical Devices</th>
<th>HealthCare IT</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Biop Medical</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Dr. Sagie Bedwetting clinics</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>EarlySense</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>GlucoMe</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>HealthWatch</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>Inovytec Medical Solutions</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>Nuvo Group</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Playwork</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Shekel Scales</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td>Vitalerter</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td><strong>Biotechnology</strong></td>
<td><strong>DYN R&amp;D</strong></td>
<td>33</td>
</tr>
<tr>
<td><strong>Estar Technologies</strong></td>
<td><strong>36</strong></td>
<td></td>
</tr>
</tbody>
</table>
## Table of Contents by Therapeutic Area(s)

### Cardiovascular
- Biobeat
- Cardiacx Medical
- Cnoga Medical
- Core Scientific Creations
- DPE Medical
- EarlySense
- HealthWatch
- Inovytec Medical Solutions
- Medispec
- Mennen Medical & MTRE
- Salute Rehab
- Sion Medical

### Dermatology & Aesthetics
- DYN R&D
- Estar Technologies
- neoLaser

### Diabetics
- BRH Medical
- B-Cure Laser
- Cnoga Medical
- GlucoMe

### EMS – Emergency Medicine Services
- Cardiacx Medical
- Cnoga Medical
- Core Scientific Creations
- Flight Medical
- Guide In Medical
- Inovytec Medical Solutions
- Medisim
- Qinflow

### ENT – Ear, Nose & Throat
- Biolight Medical Devices
- Core Scientific Creations
- Lumenis
- Mizra Medical
- neoLaser
- Pharma Sept

### Gastrointestinal
- Allium
- Exalenz Bioscience
## Table of Contents by Therapeutic Area(s)

### General Health
- Hygimed by Maabarot & Ashylon 44
- Cnoga Medical 29
- DPE Medical 31
- Equatel 35
- Exalenz Bioscience 37
- HealthWatch 42
- Medisim 49
- Mizra Medical 54
- Noam Urim 57
- Polycart Medical 63
- Shekel Scales 66
- Vitalerter 73

### General Surgery
- Core Scientific Creations 30
- Gordian Surgical 40
- Guide In Medical 41
- Mennen Medical & MTRE 52
- neolaser 56
- Pharma Sept 61
- Via Surgical 70

### Gynecology & Obstetrics
- Allium 20
- Biop Medical 25
- Core Scientific Creations 30
- DYN R&D 33
- Gordian Surgical 40
- Lumenis 48
- Nuvo Group 58
- Sion Medical 67

### ICU - Intensive Care Unit
- Flight Medical 38
- Guide In Medical 41
- Medisim 49
- Mennen Medical & MTRE 52
- Peak Medical 60

### Infection Control
- EarlySense 34
- NanoVibronix 55
- Noam Urim 58
- Sion Medical 67

### Neurology & Degenerative Disease
- Bo&Bo 26
- DPE Medical 31
- MediTouch 51
- Pharma Sept 61
- Salute Rehab 65
- Viasonix 71
## Table of Contents by Therapeutic Area(s)

<table>
<thead>
<tr>
<th>Therapeutic Area(s)</th>
<th>Company(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology</td>
<td>Biop Medical</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Core Scientific Creations</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>EarlySense</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>IceCure Medical</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>Synergy by Medical Enterprises Group</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>neoLaser</td>
<td>56</td>
</tr>
<tr>
<td>Oral &amp; Dental Care</td>
<td>Core Scientific Creations</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>B-Cure Laser</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Estar Technologies</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>neoLaser</td>
<td>56</td>
</tr>
<tr>
<td>Orthopedics</td>
<td>Bo&amp;B Bo</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>Core Scientific Creations</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>DPE Medical</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>EarlySense</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>B-Cure Laser</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Estar Technologies</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Hip Hope Technologies</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>Medispec</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>MediTouch</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>Meditrac</td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>Mizra Medical</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>neoLaser</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Pharma Sept</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td>Salute Rehab</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>Sion Medical</td>
<td>67</td>
</tr>
<tr>
<td>Pain Management</td>
<td>Medasense Biometrics</td>
<td>48</td>
</tr>
<tr>
<td>Pediatrics</td>
<td>DPE Medical</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>Dr. Sagie Bedwetting clinics</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>MediTouch</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>Mennen Medical &amp; MTRE</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>Mizra Medical</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>neoLaser</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>Salute Rehab</td>
<td>65</td>
</tr>
<tr>
<td>Peripheral Vascular</td>
<td>Core Scientific Creations</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>neoLaser</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Viasonix</td>
<td>71</td>
</tr>
</tbody>
</table>
## Table of Contents by Therapeutic Area(s)

<table>
<thead>
<tr>
<th>Therapeutic Area(s)</th>
<th>Company(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary</td>
<td>Cnoga Medical</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>DPE Medical</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>EarlySense</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>Flight Medical</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>neoLaser</td>
<td>56</td>
</tr>
<tr>
<td>Rehabilitation</td>
<td>Bo&amp;Bo</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>DPE Medical</td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>EarlySense</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>B-Cure Laser</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Playwork</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td>Hip Hope Technologies</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>MediTouch</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>Salute Rehab</td>
<td>65</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Chaban Medical</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>Cnoga Medical</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>EarlySense</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>Flight Medical</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>Guide In Medical</td>
<td>41</td>
</tr>
<tr>
<td></td>
<td>HealthWatch</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>Inovytec Medical Solutions</td>
<td>46</td>
</tr>
<tr>
<td>Urology</td>
<td>Allium</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>Core Scientific Creations</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Gordian Surgical</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Lumenis</td>
<td>48</td>
</tr>
<tr>
<td></td>
<td>Medispec</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>Synergo by Medical Enterprises Group</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>Mizra Medical</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>NanoVibronix</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Sion Medical</td>
<td>67</td>
</tr>
<tr>
<td></td>
<td>Virility Medical</td>
<td>72</td>
</tr>
<tr>
<td>Veterinary</td>
<td>B-Cure Laser</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Estar Technologies</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Medispec</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>neoLaser</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>Qinflow</td>
<td>64</td>
</tr>
<tr>
<td></td>
<td>Sion Medical</td>
<td>67</td>
</tr>
</tbody>
</table>
# Table of Contents by Therapeutic Area(s)

<table>
<thead>
<tr>
<th>Women’s Health</th>
<th>Biop Medical</th>
<th>25</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cnoga Medical</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>DYN R&amp;D</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>IceCure Medical</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>neoLaser</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>OCON Medical</td>
<td>59</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Wound Management</th>
<th>BRH Medical</th>
<th>22</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Core Scientific Creations</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>B-Cure Laser</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>Estar Technologies</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Medispec</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>NanoVibronix</td>
<td>55</td>
</tr>
<tr>
<td></td>
<td>Sion Medical</td>
<td>67</td>
</tr>
</tbody>
</table>

---

Back to: Companies ➤ Categories ➤ Therapeutic Areas
Allium Medical

**Category:** Medical Devices  
**Sub-Category:** Disposable & Implantable  
**Therapeutic Area(s):** Urology, Gynecology, Gastrointestinal  
**Company Status:** Revenue Growth

---

**Company at a Glance**

**Advanced Minimally Invasive Products**

**Description:** Allium Medical Solutions Ltd., a publicly traded company in TASE, develops, manufactures and internationally markets, from its premises in Caesarea Israel.

Our business currently includes 4 distinct product lines:

- Cardiovascular
- Urology and Continence Care
- Uro-Gynecology and Pelvic Reconstruction
- Gastroenterology

**Technology & Product(s)**

**Allium® Site Specific Stents (CE marked, TGA approved):**

Allium Medical offers long term, fully covered, expandable and retrievable metal stents. The Allium stents are anatomically and functionally compatible to specific organs for the treatment of obstructions in the urinary and GI tracts.

Allium offers physicians and patients highly effective stenting solutions for significantly enhancing clinical results and patients’ quality of life.

Allium has developed a proprietary stent technology platform to expedite the development of site-specific stents. Each Allium stent is designed specifically to match the site to be treated and the surrounding anatomy. This proprietary technological platform allows Allium to produce thin walled, entirely covered stents with a large lumen, but with the critical advantage of removability.

**EndoFast® – Soft Tissue Fixation Technology:** The EndoFast core technology is the unique Spider Fastener for soft tissue fixation of mesh to any soft tissue. The product is currently used for repair of pelvic organ prolapse and incontinence. The EndoFast clinical benefits include very high pull-out force, shallow penetration, and retrievability, which enable optimal mesh fixation.

---

**Goals**

**Objectives:** To find new distributors, OEM, private label devices, strategic business collaboration.

**Target Businesses:** Distributors, Investors, Strategic Partners.

**Target Countries:** Nordic Countries, Latin America, India, Japan, Thailand, Indonesia.
B-Cure Laser

Company at a Glance

B-Cure Laser Pro- Diabetic Foot Ulcers- NEW outstanding Double blind CLINICAL TRIAL RESULTS

B-CURE LASER is the world’s first portable Evidence base Low Level Laser Therapy (LLLT) medical device with the Healing Power of a clinic: For treating efficiently hard to heal wounds, Orthopedic conditions, and to alleviate pain. Our goal is to bring innovation in treatment, medical care, and quality of life.

New double blind clinical trials for both wound healing and orthopedic conditions support the efficacy.

Diabetic Foot Ulcer CLINICAL TRIAL- results:

Preliminary results of a double blind clinical trial: 7 of 10 patients of the active B-cure Laser Pro group had >90% wound closure, (4 had a complete closure); vs only 1 of 9 of the placebo group, within up to 12 weeks of treatments, p=0.019 by Fisher Exact Probability Test. Comparing % closure-Placebo vs Active:

16% vs 84.6% in the Active group, P=0.033 by 2 sided exact Mann-Whitney U test. Both groups were treated in addition with gold standard same dressings.

The treatment method is also significantly effective to treat pressure wounds, cuts, burns, and post operation wounds.

Products:

B-Cure Laser- Efficient treatment of Orthopedic conditions, Pain and Rehabilitation – Easy and safe for home use.

B-Cure Laser PRO- for the treatment of Acute and Chronic wounds, including Diabetic Foot Ulcers – Increased laser emission, 5 joules per minute.

B-Cure Laser Sport – the professional solution for orthopedic conditions, sports pain, and sports injuries. It is the official Medical Device of the Israeli Olympic committee following a series of successes in treating professional athletes and sportsmen.

Technology & Product(s)

B-CURE LASER is a technological breakthrough in Soft Laser Therapy and is recommended for both professional and personal treatment and recommended by leading Doctors.

A new adjustable stand helps to hold the Device in place.

B-CURE LASER patent: An Exclusive electro-optic mechanism which combines a high power and full coherence of the laser beam, covering a large area of 4.5 cm², in a portable, rechargeable, safe and easy-to-use device, resulting in fast healing and recovery. No goggles are required.

Goals

Objectives: To find Partners for a joint venture/Distributors.

Target Businesses: Hard to heal wound clinics, Hospitals, Home Care services, end users for self-treatments at home, Pharmacies – a unique business model, Pain clinics, Sports teams and Associations, sports men, athletes, security forces, nursing homes, Physiotherapists, Dentists.

Target Countries: Worldwide- all countries. In some countries we have already distributors for one or more of our models.
BRH Medical, Ltd.

**Category:** Medical Devices  
**Sub-Category:** Medical Equipment  
**Therapeutic Area(s):** Wound Management, Diabetics  
**Company Status:** Clinical Trials, Initial Revenues  
**www.brhmedical.com**

---

### Company at a Glance

BRH Medical develops, manufactures and markets high technology solutions for the care and treatment of chronic wounds. Founded by Ilan Fefferberg, a serial entrepreneur, and headed by Motti Oderberg, a successful businessman and entrepreneur, the company’s goal is to develop the gold standard in chronic wound treatment and become a leader in the field. The company's first product, BRH–2A, is currently being used successfully in wound clinics around the world and has proved effective in closing wounds in several clinical studies.

The BRH–2A system implements a novel, patented technology that combines therapeutic ultrasound and electrical fields at varying frequencies and intensities. The BRH System is the only one of its kind to include an advanced database for patient and wound management, together with an accurate wound measuring and documentation platform.

### Technology & Product(s)

BRH Medical develops and manufactures the BRH–2A system for the treatment of chronic wounds, specifically diabetic foot wounds and venous leg ulcers. The BRH system implements a novel, patented technology that combines therapeutic ultrasound with electrical fields. The BRH System also includes an accurate wound measuring and documentation platform for patient and wound management.

The BRH technology facilitates the healing of deep wounds by stimulating the wounded region using a combined ultrasound and electric field modality to encourage increased blood circulation to the wound. The ultrasound waves are transmitted at specific frequencies and intensities to the wounded region of the body and works simultaneously with the electric fields.

The BRH System has proven success in the reduction of wound pain as well as wound closure. A published study showed that after only one month of treatments, more than 50% of the Diabetic Foot Ulcers responded positively and resulted in wound closure. These results were consistent with the clinical results of a study of Pressure Ulcers recently completed.

The BRH System is currently installed in leading wound clinics around the world, including Australia, South Africa, England, Italy, Singapore, Taiwan and Israel with over 800 patients benefitting from over 12,000 treatments.

The BRH System meets ISO quality requirements and has received the CE mark, TGA and has made its submission to the FDA.

---

### Goals

**Objectives:** Identify potential partners and distributors.  
**Target Businesses:** Similar companies, agents distributors.  
**Target Countries:** Germany, U.K., Netherlands, France, Spain, Italy, USA, China.
Biobeat Ltd.

Category: Medical Devices  
Sub-Category: Telemedicine  
Therapeutic Area(s): Cardiovascular  
Company Status: Regulatory Approval  

Company at a Glance

Biobeat develops a cutting-edge wearable monitor for remote non-invasive accurate medical-grade monitoring of vital signs and other medically relevant parameters.

Biobeat’s system facilitates remote monitoring of patients with a variety of medical issues. Ultimately, Biobeat’s solution allows patients to be treated at the comfort of their homes, rather than in the hospital. Biobeat’s solution allows for monitoring of stationary patients, but also patient who are up and about including during outdoor activities.

It is our mission harness technology to allow for cheaper, better and more convenient patient care.

Real time remote monitoring

Biobeat introduces a new concept of continuous vital-signs measurements ANYWHERE and ANYTIME. Biobeat’s wearable automatically uploads monitoring data to a smartphone based app and to the cloud, where it can be monitored remotely. Caretakers may intervene as signs raise alert and user may receive alerts directly from the app. This provides caretakers with an important tool to assist in disease management and to optimize clinical outcomes.

Data history

Biobeat’s solution collects your data in real time, all the time, and saves it in Biobeat’s cloud based data-center. Biobeat keeps your information and presents you the data graphically in an easily comprehensible manner.

Technology & Product(s)

Biobeat’s technology measures vitals in a non-invasive and simple manner allowing continuous and accurate monitoring.

The system provides a combination of abilities which are not currently offered in one single device due to technological barriers.

Goals

Objectives: Investments and businesses.  
Target Businesses: Sale product.  
Target Countries: U.S.A and Europe.
BioLight Medical Devices

**Category:** Medical Devices  
**Sub-Category:** Medical Equipment  
**Therapeutic Area(s):** Allergy, ENT - Ear, Nose and Throat  
**Company Status:** Revenue Growth

---

**Company at a Glance**

BioLight is the producer of electronic phototherapy devices, based on low level narrow band red light. Our devices offer non-invasive, drug-free, side-effect-free treatment for: hay fever, oral lesions, chronic pain and rheumatoid arthritis as well as acne and chronic wounds.

BioLight recently developed the new BioNette, a sophisticated second generation of the original BioNase that very effectively treats hay fever (allergy rhinitis).

Allergic rhinitis is a 21st century disease unknown before the 18th century. Researchers predict that within 20 years 50% of western population will suffer from it (today it is estimated that approx. 20%-25% of the population suffers from allergic rhinitis).

Due to the BioNette's unique design and technology, it has already been chosen by some of the world’s largest retailers and distributors including:

- **Boots (UK),** the largest health and beauty chain in the world,
- **Sinopharm (China),** the largest pharmaceutical conglomerate in China,
- **Hanmi Medicare (Korea),** the second largest pharmaceutical conglomerate in Korea,
- **Wholesale Medical Network (WMNI, Canada),** a very respected wholesaler in Canada
- **Probiomed (Mexico),** one of a largest Mexican wholesaler
- **Marpel Pharma (Central America),** a leading pharmaceutical distributor
- **Gala Optics (Russia),** a leading medical distributor
- **Neurofharma (Colombia), MacroTel S.A. (Chile), Almed Group (Turkey), Interlux (Baltic)**

---

**Technology & Product(s)**

- **BioStick** – a personal device for treating aphthas, gingivitis, cold sores etc.
- **BioBeam 660** – for treating acne and non-healing wounds
- **BioBeam 940** – for relieving rheumatic arthritis pains

---

**Goals**

- **Objectives:** BioLight is looking for reputable distributors and wholesalers to collaborate in the selling and marketing of the BioNette.
- **Target Businesses:** Medical devices distributors, wholesalers and investors.
- **Target Countries:** Europe, Other territories.
Biop Medical

Category: Medical Devices, Healthcare IT  
Sub-Category: Diagnostic & Monitoring, Endoscope & Accessories, Imaging  
Therapeutic Area(s): Oncology, Gynecology, Women’s Health  
Company Status: Clinical Trials

Company at a Glance

Biop Medical is an Israeli medical device startup, which has developed an innovative technology for the identification of cancerous cells in epithelium tissues. The technology is a platform technology, which will be implemented in a number of devices for cancer screening and diagnosis, beginning with cervical cancer. Cervical cancer is the second most common cancer among women worldwide.

Biop’s real-time screening tool offers standard colposcope capabilities with state-of-the-art, enhanced features. The novel device combines advanced, high-resolution optics with integrated micro and macro cameras and other optical elements to produce highly sensitive optical signatures for automatic identification of suspicious areas and quantification of the cancer stage. The collected data is combined and analyzed using Biop’s proprietary algorithm. Preliminary commercialization of Biop’s proprietary transducer will replace current colposcopy and other existing cervical screening technologies.

Technology & Product(s)

Biop Medical is an Israeli medical device startup, which has developed an innovative technology for the identification of cancerous cells in epithelium tissues. The technology is a platform technology, which will be implemented in a number of devices for cancer screening and diagnosis, beginning with cervical cancer. Cervical cancer is the second most common cancer among women worldwide.

Biop’s real-time screening tool offers standard colposcope capabilities with state-of-the-art, enhanced features. The novel device combines advanced, high-resolution optics with integrated micro and macro cameras and other optical elements to produce highly sensitive optical signatures for automatic identification of suspicious areas and quantification of the cancer stage. The collected data is combined and analyzed using Biop’s proprietary algorithm. Preliminary commercialization of Biop’s proprietary transducer will replace current colposcopy and other existing cervical screening technologies.

The Advantages of our Technology:

• Enables diagnosis of cancer and pre-cancerous tissues
• Automatically scans entire cervix for point-of-care diagnosis
• Generates a real-time map of the cervix for accurate biopsy, when necessary
• Eliminates dependency on operator proficiency due to software analysis
• Reduces the wait time (and associated anxiety) between testing and diagnosis
• Generates data sets for “big data”

The company has graduated from the first ever IBM accelerator and has already developed its first commercial revolutionary optical probe according to FDA regulations. Biop has completed a multicenter study in Europe and continues clinical studies in Europe and in Israel. The results of which are promising.

Goals

Objectives: Seeking potential strategic partners and investors in order to advance to the commercialization stage.

Target Businesses: Strategic partners, hospitals, Distributors, Venture Capital, Investors.

Target Countries: Germany, UK, France, Italy, Holland, USA, Canada, China.
Bo&Bo Ltd.

Category: Medical Devices
Sub-Category: Medical Equipment
Therapeutic Area(s): Orthopedic, Rehabilitation, Neurology and Degenerative Disease
Company Status: Initial Revenues, Regulatory Approval

Company at a Glance

BOBO is a revolutionary training board that converts traditional balance devices into interactive gaming platforms. This technology dramatically increases patient engagement and enables performance measurement and personalized treatment.

BOBO was successfully launched in March 2016 in Israel, targeting the professional training and rehabilitation market – both in commercial institutions and on a consumer level as well. Our clients include leading Hospitals, HMO’s, Physical Therapy Practices, Personal Trainers, Exercise Centers and the IDF - Military.

BO&BO teamed up with leading medical and nursing centers, in performing field research and testing of the device. BO&BO is ISO 13485 certified and obtained CE-mark and FDA listing for BOBO™.

Technology & Product(s)

BO&BO is introducing two new training products:

1. boboPRO: Designed for professional use by clinicians and healthcare providers, is a smart board that mounts traditional balance training products. Enable wide range of training poses and Meets all exercise levels + a tablet based console, controlled by the smart board movements. Runs hundreds of tilt based games and supports professional training programs.

The BoBoPRO system is user-friendly, just plug-and-play. Based on the Android OS and an intuitive UI. It can easily be mounted on a wall, a table or be used outdoors -- guaranteeing simple and smooth practice sessions. Not only is The BoBoPRO affordable but cost effective as well. BoBoPRO guides the user from A to Z, freeing up the trainer to treat more than one patient at once.

2. boboHOME: Designed for home users, is a smart mini-board that connects to the user’s smartphone and can be used anywhere. Offering fun balance games and professional training sessions at affordable price and friendly interface.

BOBO personal AI trainer - analyze user performance and customize programs based on advanced algorithms. Data is collected during the training session and automatically processed to detailed reports for further clinical and business analysis.

Goals

Target Businesses: Distributers, Hospitals/rehabilitation clinics, private physiotherapists.
Target Countries: Worldwide.
CardiacX Medical Ltd.

Category: Medical Devices
Sub-Category: EMS - Emergency Medicine Services
Therapeutic Area(s): Cardiovascular
Company Status: Regulatory Approval

Company at a Glance
CardiacX Medical is developing, manufacturing and marketing novel cardiac resuscitation solutions including the World’s 1st miniature Personal External Defibrillator (PED). Remarkably small, like a thick smartphone, it is able to deliver the same energy (200 J) and number of bi-phasic pulses (at least 5) like a regular public AED.

The PED marks a dramatic impact on the OUT-OF-HOSPITAL survival rate of victims of a Sudden Cardiac Arrest:

The PED will raise dramatically the OUT-OF-HOSPITAL, from today’s survival rate of only 5% (1 survivor from 20 victims) up to the IN-HOSPITAL survival rate of 50% or more (1 in 2 victims will survive).

Also, by being with the patient all the time, the PED will make the survival rate independent of the victim’s location, if the victim is at the gate of a hospital where the survival rate is high or in a trip in an isolated place in the mountains where the survival rate is practically 0.

Technology & Product(s)
Inventive energy storage technologies allow packing the same energy of the large public defibrillators (AED) in a remarkably small case of a smartphone, thus making CardiacX’ PED the World’s 1st truly personal defibrillator that can fit in the front pocket of a shirt.

Goals
Objectives: Establishing strategic connections with leading resuscitation medical device distributors. Set worldwide distribution channels for our PED. Develop strategic partnerships on commercial and technological levels.
Target Businesses: B2C.
Target Countries: Worldwide.
Chaban Medical Ltd.

**Category:** Medical Devices  
**Sub-Category:** Medical Equipment  
**Therapeutic Area(s):** Respiratory, Dermatology & Aesthetics  
**Company Status:** Revenue Growth  

### Company at a Glance

Established in 2013, develops and manufactures medical devices, holds: ISO 14001, ISO 13485, ISO9001, clean room ISO-7 certifications, business license 1.3 for medical development & manufacturing. Certified by the U.S. Food and Drug Administration (FDA) and holds the CE Marking of European Union.

### Technology & Product(s)

**Oxy-Tec 5S Oxygen Concentrator:**

The new Oxy-Tec 5S has been specially developed to provide a dependable, convenient source of supplemental oxygen for therapeutic needs. Chaban had recently developed an add-on monitoring device (optional) for monitoring the devices performances and send the data to the cloud. By doing so it's ensure:

- Proper operation by the patient.
- Preventing malfunctions.
- Shorter seller’s response time.
- Characterization of malfunctions and the manner of handling them remotely.

System maintenance and general data such as oxygen level, flow rate, hour counter, filters exchanging time et cetera.

**CryoNeedle (cryosurgical Needle):**

The **CryoNeedle** Cryoprobe, FDA approved, is a hand-held cryosurgical instrument for destroying tissue of Hypertrophic Scars and Keloids (HSK) during surgical procedures by intralesional application of extremely cold cryoprobe. The device is based on intralesional application of a needle cooled by the cryogenic fluid (liquid nitrogen with boiling temperature −196°C (−320.8°F)) to a selected area to effect cellular destruction.

**Product Advantages:**

- Significant reduction in scar volume after a single treatment, thus most cases require only a single session.
- Quick alleviation of pruritus, pain, discomfort and tenderness.
- Minimal or no hypopigmentation or other side effects.
- The procedure consists of a single needle insertion (excluding local anesthetic), allowing the patient to leave the clinic immediately following the treatment.
- Large scars can also be treated using the CryoShape.
- Multiple scars may be treated in a single session.
- In most cases (>97%) no scar recurrence is observed.

Clinically no worsening of scar or infection has been observed. For use in homecare, hospitals, clinics, assisted living centers/nursing homes.

### Goals

**Objectives:** Locating local distributors.  
**Target Businesses:** Sales, Medical Device Distributers.  
**Target Countries:** Europe, Latin America, Africa, India.
Cnoga Medical Ltd.

Category: Medical Devices
Sub-Category: Diagnostic & Monitoring, Telemedicine
Therapeutic Areas: Diabetics, Endocrinology, Cardiovascular, EMS – Emergency Medicine Services, General Health, Pulmonary, Primary Care, Respiratory, Women’s Health

Company Status: Revenue Growth

Company at a Glance

Cnoga Medical Ltd., a privately owned Israeli company develops and distributes innovative Non Invasive medical monitor devices. The unique algorithm analyzes the image sensor data to provide 14 Bio Parameters analysis. Cnoga devices are portable and easy to use. Patient simply place his finger in the device and the automatic measurement provides the 14 blood parameters in a minute. Results can be transmitted to a secure server for review and filing.

The TensorTip Noninvasive devices: CoG Glucometer
Non Invasive, needle-free Glucose monitoring for Diabetics. Based on a personal calibration the CoG provides diabetic patients with an accurate Non invasive solution to measure blood glucose.

VSM (Vital Sign Monitor)
A Small Non Invasive Monitoring device measuring continuous Blood Pressure without arm cuff, Pulse,SpO2 and optional 3 additional parameters (Hgb, HCT, RBC or pH, PCO2,PO2).

MTX (14 bio parameters)
Measure noninvasively blood hemodynamics & Blood chemistry: Hemoglobin, Hematocrit, RBC, Blood Pressure (No cuff!), Pulse, Saturation, Cardiac Output, MAP, SV, PO2, PCO2, and Waveforms.

Regulatory Status:
- Europe: CE mark approval for Non Invasive Combo Glucometer, VSM and MTX.
- China: CFDA marketing approval for MTX & VSM and CoG
- Israel: AMAR approval for Non Invasive Combo Glucometer, VSM and MTX.
- USA: FDA approval for the Blood pressure and Pulse.
- Brazil: ANVISA approval for Non Invasive Combo Glucometer, VSM and MTX.

Technology & Product(s)

CNORA raised $50M in early 2017 from a strategic partner in China. CNOGA’s Tensor tip technology is based on innovative, non destructive and reliable spectral anlysis patented algorithm within a small medical devices. This technology enable point of care rapid measurement of up to 14 Bioparameters such as Blood hemodynamics, blood gases and blood chemistry in a manner of minuts, anywhere and anytime.

CNOGA TensorTip™ Matrix™ (MTX) securely measures, monitors and analyzes more than a dozen blood parameters non–invasively – Blood pressure, Stroke Volume, Cardiac Output, Cardiac Index, as well as Blood Gases (CO2, O2, pH), Hemoglobin, Hematocrit, Red Blood Cell, Pulse and Main Atrial Blood Pressure and more.

CNOGA TensorTip™ Combo Glucometer (CoG) provides a revolutionary, painless and non–invasive approach to glucose measurement, enabling diabetics to monitor their glucose levels everywhere with no prick and no blood. This device is individually calibrated for each patient and is designed for everyday use.

CNOGA TensorTip™ VSM™ tracks Blood Pressure, Oxygen Saturation and Pulse per Minute and offers, like all CNOGA devices, non–invasive and ease–of–use measurements.

CNOGA Singular is CNOGA’s secure cloud infrastructure, designed to safely transfer medical results from the devices to CNOGA’s mobile application and allows secure access to caretakers, physicians or other selected stakeholders.

Goals

Objectives: Searching for medical distributors Europe, USA, Canada, India, China.
Target Businesses: Distributors.
Target Countries: North America, Europe, China, India and others.
Core Scientific Creations Ltd.

Category: Medical Devices
Sub-Category: Disposable & Implantable
Therapeutic Area(s): Wound Management,
EMS – Emergency Medicine Services, General Surgery,
Cardiovascular, Oncology, Orthopedic, Nephrology,
Oral & Dental Care, Obstetrics, Gynecology, ENT – Ear,
Nose and Throat, Urology, Peripheral Vascular
Company Status: Revenue Growth

Company at a Glance
Core Scientific Creations develops and manufacturing medical device in the field of Advanced Bleeding control. It is our mission to change the way bleeding is treated in the hospital, in the field and at home. We save lives by developing cutting edge technologies to control all types of bleeding faster, safer and smarter. We are first and foremost a scientific company dedicated to bringing knowledge and proven products to the end user.

Technology & Product(s)
WoundClot is an innovative hemostat, uniquely engineered to control non-compressional mild, moderate and severe bleeding in and out of hospital arena, by professionals and untrained care givers.
- The only bio-absorbable hemostat approved for severe arterial bleeding.
- First true non-compressional hemorrhage control in the market.
- Stops all types of bleeding fast (vascular, soft tissue, bone, lungs and severe traumatic hemorrhage)
- Promotes coagulation for coagulopathic patients.
- Fully absorbed in the body within c.a 7 days.
- Creates a biological clot.
- The only non-oxidized cellulose hemostat.

IN BLOOD WE CLOT

Goals
Objectives: To introduce life saving technologies, for the harshest bleeding scenarios both in the hospital and pre hospital environments. Equipping caregivers with an extensive scientific knowledge base to help make life saving decisions, both in Critical and calm environments.

Target Businesses: Distributors end-users in the fields of hospital and pre hospital emergency environments as well as surgical and applications for internal bleeding control, neurology surgery, Cardiac Catheterization Lab, OBGYN, ENT applications. EMS providers and military/governmental care givers and dental disposables distributors.

Target Countries: European Union, USA/North America, EMEA, Eastern European countries, Australia, Asian market and South America.
Dpe Medical Ltd.

**Category:** Medical Devices
**Sub-Category:** Medical Equipment, Robotics, Diagnostic & Monitoring, Research Equipment, Training, Telemedicine
**Therapeutic Area(s):** Rehabilitation and physiotherapy, Cardiovascular, Neurology and Degenerative Disease, Neuroscience, Orthopedic, Pediatrics, Pulmonary, General Health
**Company Status:** Revenue Growth

**Company at a Glance**

Total Stairs and Gait Training Solutions.
Dpe Medical is a unique international company that specializes in the development and manufacture of revolutionary products in the field of physiotherapy and rehabilitation.
Close collaboration with senior and experienced physiotherapists, together with an outstanding research and development department, creates fruitful soil for new and unique products.

**Technology & Product(s)**

Dpe Medical provides total Stairs and Gait Training Solutions.
For 15 years, our products helped millions of patients throughout the world to return to their daily life.
Professional physiotherapists, repeatedly, year after year choose the **Dynamic Stair Trainer** as the preferable tool to train and rehabilitate their patients.

Walking and stairs climbing are basic and fundamental skills needed for mobility and well-being.
Dpe Medical’s products where developed specially to meet these needs.
Thousands of physiotherapists and millions of patients put their faith at the Dynamic Stair Trainer.
Today, **DST** is a synonym for efficiency and excellency when referring to physiotherapy and rehabilitation products.

During 2017, Dpe Medical ltd. launched and installed the first, state of the art, **DST TriplePro**. The **DST TriplePro** enables, for the first time, to monitor, document and improve stairs climbing, gait training and incline walking.
Physiotherapy departments and Institutes now have full documentation of all sessions of stairs climbing conducted with their patients, accompanied by an individual Progress Chart of (with **DST Factor**) each patient.

**Goals**

**Objectives:** Presenting new products, Recruiting new distributors.
**Target Businesses:** Distributors in the field of physiotherapy and rehabilitation.
**Target Countries:** Australia, Austria, Belgium, Bulgaria, Brazil, Canada, China, Costa Rica, Cyprus, Czech Republic, Denmark, Estonia, France, Hungary, Ireland, Italy, Kazakhstan, S. Korea, Kuwait, Latvia, Morocco, Netherlands, Portugal, Qatar, Philippines, Romania, Saudi Arabia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, Uzbekistan, Vietnam.
Dr. Sagie Bedwetting Clinics

Category: Healthcare IT
Sub-Category: Internet-based health info
Therapeutic Area(s): Pediatrics
Company Status: Revenue Growth

Company at a Glance

“Dr. Sagie Bedwetting Clinics” is an Israeli family business, established in 1984 by Dr. Jacob Sagie, Ph.D., Enuresis Specialist. His son, Tal Sagie joined in 1999. They operate 9 bedwetting clinics in Israel as well as clinics in New York. They have treated patients from all over the world. Dr. Sagie was the founder and director of the enuresis clinic of Schneider Children Medical Center (SCMC) since 1994. The unique Multi-Modality face-to-face treatment was developed by Dr. Sagie, based on clinical and research experience with an over 40,000 patients, age 4–35 and produces an over 90% success rate. This treatment model was transferred into an online web-based treatment called TheraPee. The entire product (device and software) was developed and manufactured in Israel. It is on the market since 2013 available in English, Spanish, Hebrew and Turkish. We’re planning to penetrate into new markets such as Germany, France, U.K, India, China, Japan, Korea, Arab countries and more by offering the product in more languages. We are looking for potential and appropriate partners in order to distribute our products in the targeted markets. TheraPee’s annual growth is more than 80%. Since the worldwide target population is enormous and no proper solution is being offered, the economic potential is very high.

Technology & Product(s)

TheraPee – A unique, innovative solution for bedwetting. A combination of an exclusively developed device together with sophisticated software and unique tailor-made treatment plan. We transferred our Multi-Modality Enuresis Treatment into an Interactive Enuresis Web Home-based software program called TheraPee. We identified and gathered every possible scenario on our current treatment process and every possible profile of enuretic patient. We developed numerous sophisticated and complex algorithms. By using those algorithms, we can offer a similar response to the one given in our clinics. The system analyzes the provided data and the algorithm chooses the right response. The response is given to the patient via a video clip. In those clips the “virtual therapist” will address the patient and his parents, giving feedback concerning the patient’s progress.

Advantages:
• The first and only online bedwetting treatment in the world, which allows every child worldwide to get outstanding results from the comfort and privacy of their own home.
• More than 90% success rate
• No geographical and language barriers.
• The price is a fraction of the cost compared to in-person programs.
• Medication free.
• Helps the environment by saving on pull-up use.
• Totally private and confidential. No embarrassing situation in a doctor’s office.
• The most advanced device on the market, 100% safe and meets all the FDA and CE requirements.

During 2017, Dpe Medical ltd. launched and installed the first, state of the art, DST TriplePro. The DST TriplePro enables, for the first time, to monitor, document and improve stairs climbing, gait training and incline walking. Physiotherapy departments and Institutes now have full documentation of all sessions of stairs climbing conducted with their patients, accompanied by an individual Progress Chart of (with DST Factor) each patient.

Goals

Objectives: Looking for strategic partners and distributors.
Target Businesses: Partners, International vendors, Distributors, Health Insurance, Hospitals.
Target Countries: Germany, France, U.K, India, China, Japan, Korea, Arab countries.
DYN R&D

Company at a Glance

DYN R&D was founded in 2002 as a development and commercialization subsidiary of DYN Diagnostics Group, since 1990 one of Israel’s largest distributors of leading international brands in the fields of In-Vitro Diagnostics, Medical Devices, Over-the-Counter Products, Disposables and more. Spurred by the innovative spirit and startup atmosphere that drive the Israeli market, DYN R&D decided to harness its extensive knowledge and experience to launch into the world of research and development. DYN Diagnostics’ professional reputation put DYN R&D at the forefront of opportunities and collaboration with opinion leaders, research facilities and health institutes. DYN R&D creates advanced solutions to both Medical Devices and Molecular Diagnostics fields. In addition, DYN R&D offers customized solutions tailored to individual customer needs, such as medical-platform interfaces and genetic markers that enable diagnosis that is more accurate and personalized treatment of medical conditions. DYN R&D also specializes in Genetic Agriculture Marker Analysis. Due to growing demand for solutions in the field of Agricultural Biotechnology, in 2008 DYN R&D launched the Genotype® brand, offering unique DNA markers and smart breeding solutions. DYN R&D complies with the ISO 13485:2003 international standard for medical devices and maintains a full quality management system.

Technology & Product(s)

CIN Finder 3000 Digital Colposcopy System

The CIN FINDER 3000 Colposcopy System offers GYN physicians a complete solution for colposcopy examinations and documentation. The CIN FINDER 3000 is a “one stop” system, which combines the CIN FINDER 3000 patient management software with a top-of-the-art HD video colposcopy camera, a medical grade all-in-one computer and a customized, space efficient operator cart. The integrated systems provide physicians with the necessary tools to perform the entire examination process from a single platform. The CIN FINDER 3000 software was developed with the assistance of key opinion-leader physicians from both the common cervix examination and sexual assault fields in Israel. The software is designed to provide physicians with a user-friendly approach for examination, image storage and annotation, image comparison, pathological report management, data summarization, patient follow-up and more.

CIN FINDER software is available in two different applications – Cervical Examination and Sexual Assault Documentation. The functions of each application are suited to the common procedures and protocols of each of the disciplines. The glossary of each platform is based on professional examination terms, with the cervix examination platform also based on the updated Bethesda (TBS) colposcopy guidelines. DYN R&D has more than 10 years of experience in the colposcopy field in Israel, specifically in cervical clinics, sexual assault centers and emergency rooms for adults and children.

System’s Key Features: Full courses of examination built with key opinion physicians; Professional glossaries based on Bethesda (TBS) colposcopy guidelines; User-friendly interface; Sharp and vivid HD image; Excellent HD color definition with optical zoom; Efficient patient management tools; CE-approved; Coming Soon: Integration with HL7 and compliance with DICOM standards

Goals

Objectives: To provide innovative, accurate and fast solutions while maintaining high levels of reliable customer service.
Target Businesses: Medical Device Distributors.
Target Countries: All EMEA countries.
EarlySense

Category: Medical Devices, Healthcare IT
Sub-Category: Diagnostic & Monitoring, Telemedicine, EHR
Therapeutic Area(s): Cardiovascular, Infection Control, Internal Medicine, Oncology, Orthopedic, Rehabilitation, Respiratory, Psychiatry, Pulmonary
Company Status: Initial Revenues, Revenue Growth

Company at a Glance

Founded in 2004, EarlySense is the market leader in contact-free and continuous monitoring technology. Validated in peer-reviewed studies and hospital installations around the world, EarlySense’s unique, sensing technology continuously monitors patients’ vital signs to improve care, save lives and reduce costs. EarlySense’s FDA/CE-cleared products have been successfully applied in numerous healthcare environments such as hospitals, nursing homes, rehabilitation centers and long-term care facilities. The company has partnered with distributors in the US, Europe, Southeast Asia and Australia, and is credited with saving hundreds of lives and saving millions of dollars each year in reduced hospital days, patient falls, adverse events and more.

In addition, EarlySense’s patented technology lies at the heart of numerous consumer digital health systems such as Samsung’s SleepSense, Beurer’s Sleep Expert and iFit’s Wellness Platform.

The company recently released its own consumer product, which will be tailored for the elderly population with remote viewing options.

Technology & Product(s)

EarlySense’s system addresses the specific requirements of clinical teams taking care of patients, enabling them to continuously monitor them rather than just “spot check” once every few hours. The system is comprised of a unique sensor placed under the patient’s mattress, a bedside monitor, a central display station and smart mobile devices. It provides continuous monitoring for heart and respiratory rates and trends, enabling the clinical staff to identify patient deterioration early and prevent potential adverse events such as falls, decubitus (pressure ulcers) and helps support early detection of sepsis hospital protocols.

EarlySense’s technology is also available as an integration module that allows companies and developers to integrate and expand its use in their own products and services. The integration supports any combination of the main EarlySense modules – respiratory rate, heart rate, prevention of pressure ulcer / decubitus, prevention of patient falls and sleep analysis.

In addition, EarlySense’s patented technology lies at the heart of numerous consumer sleep tracking and digital health systems such as Samsung’s SleepSense, Beurer’s Sleep Expert and iFit’s Wellness Platform.

Goals

Objectives: To locate business partners for commercial and development purposes, strategic partners for integrating and implementing EarlySense technology.

Target Businesses: For our hospital solution – patient monitoring companies, hospital chains, distribution companies. – For our integration solutions – bed manufacturers, patient monitoring companies, Tele monitoring, Remote monitoring, Sleep and Apnea monitors manufacturers, home health care/ambient assisted living equipment. For our home solution – home care distribution companies, home care service providers.

Target Countries: EMEA, Asia Pacific.
Equatel addresses the following unmet needs: Connecting rural communities with public healthcare kiosks/services, 24/7 on-site availability/usage, and pre-screening solutions for urban hospitals and doctors. Equatel's clients use the Equatel Telehealth platform within various demographics:

- Corporate centers, on-site medical/consultation rooms
- Condominiums and upscale residencies
- School campuses and educational centers
- Rural clinics and out-reach programs
- Homecare services
- Admittance/pre-screening services within urban hospitals

Equatel Health offers the world’s most advanced telemedicine Kiosk and EHR platform running on any 3G, 4G, Wi-Fi and Satellite network, that includes:

1) Public access health kiosks.
2) A range of premium e-Health services, such as, e-consultations and on-site diagnostics with FDA certified integrated medical peripherals.
3) Complete EHR management platform that centralizes and organizes all patient data (health records, prescriptions, etc.), advanced healthcare analytics, and a fully integrated mobile money platform.

The global advancement in digital healthcare is a fundamental reason behind the increasing demand for Equatel's telemedicine infrastructure and solutions. Equatel Health provides relevant and substantial business/revenue opportunities for a wide-range of healthcare and telecom operators. Equatel's healthcare projects are unique and highly profitable due to our open-minded approach to collaborate with partners in all sectors. Equatel offers multiple financial models, including: Capex, OpEx, hybrid, and financed pay-per-use. This enables Equatel to structure customizable revenue opportunities for our clients; ensuring that their projects have long-term sustainability and success. Equatel Health largely focuses its efforts on the untapped and underserved emerging markets; in-which evolving variables such as, growing middle classes, critical mass, and internationally funded infrastructure projects are key ingredients to sustainable commercial success.

**Technology & Product(s)**

- Public access health kiosks.
- A range of premium e-Health services, such as, e-consultations and on-site diagnostics with FDA certified integrated medical peripherals.
- Complete EHR management platform that centralizes and organizes all patient data (health records, prescriptions, etc.), advanced healthcare analytics, and a fully integrated mobile money platform.

**Goals**

**Objectives:** Bringing the most advanced digital healthcare solutions to the Health and mobile operators as new source of well-being for the people, and new business opportunity for the Health and Telecom world.

**Target Businesses:** Health Operators (hospitals, doctors and health insurance), Mobile operators and NGO’s.

**Target Countries:** India, all countries in Africa and in South America, South East Asia.
Estar Medical

Category: Medical Devices, Biotechnology
Sub-Category: Medical Equipment, Tissue Engineering & Cell Therapy, Biomaterials & Plasma Products, Diagnostic Kits
Therapeutic Area(s): Dermatology & Aesthetics, Orthopedic, Oral & Dental Care, Veterinary, Wound Management
Company Status: Revenue Growth

Estar Medical is a privately held company operating in the Cell Therapy/Biologics/Regenerative Medicine fields. Estar Medical is known for being the inventor of the “Tropocells®” and “Cellenis®” Platelet Rich Plasma Systems (“Tropocells PRP” or “Cellenis PRP”) – offering a unique and extremely effective way to enhance and promote a significant platelet rich plasma production. Tropocells® and Cellenis® PRP (FDA & CE approved) are revolutionary repair systems that use the body’s own growth factors for wound/skin repair and rejuvenation.

Estar Medical has developed an advanced products portfolio for a variety of medical applications, such as: aesthetics/dermatology, hair-restoration, orthopedics & sports medicine, wound care, dentistry, veterinary, pain management and ophthalmology. Estar Medical currently sells its product lines, in more than 50 countries worldwide under several brand-names, being the #1 selling PRP kit for aesthetics and dermatology in the US. Estar Medical prides itself for its innovative intellectual property related to a range of therapeutic areas as well as for creating the next generation of biological products. The Company’s efforts yield highly promising results backed by clinical studies. The products roadmap is based on the “Tropocells®” platform technology and consists of the following products:

- Novel PRP-based regenerative products combining PRP with hyaluronic acid, collagen or bone substitutes
- BMAC System for concentrating bone marrow aspirate-derived cells
- Tropokine™ – autologous IL-1-RA enrichment system
- Autologous biological glues
- Autologous thrombin
- Advanced stem-cells therapeutics

Technology & Product(s)

The “Tropocells®” /”Cellenis®” PRP is a revolutionary promising approach in tissue regeneration which concentrates the patient’s own cells (platelets) in a small amount of plasma. Upon injection into the treated area, these cells release a large amount of growth factors which immediately thereafter create a synergistic effect for maximize regenerative results. to the treated site.

Among the key advantages of the Tropocells®/Cellenis® Platelet Rich Plasma systems:

- Only 10 minutes centrifugation to obtain pure PRP with its growth-factors without Red Blood Cells and Granulocytes;
- Expensive capital equipment is not required – simple low cost fix or swing centrifuge perfectly works with the Tropocells® and Cellenis® PRP;
- The simple preparation process takes no more than 10 minutes from blood collection to PRP harvesting, ensuring optimum concentration of platelets and their growth factors;
- The flexible and easy to use system enables the users to obtain higher/lower concentration by simply adjusting the amount of clear plasma removed from the tube;
- Proprietary gel separator and filtration method ensures the outcome of a clear PRP;
- Activation and clot formation can be achieved for dental and wound healing applications;
- Tropocells® is US patented, FDA cleared (510K for orthopedic applications) and CE certified.

Goals

Objectives: Finding New distributors and strategic partners.
Target Businesses: Expanding Estar Medical’s global operations.
Target Countries: North-America, Central-America, Europe, Australia, India, Far-East, Africa.
Exalenz Bioscience

Category: Medical Devices
Sub-Category: Diagnostic & Monitoring
Therapeutic Area(s): Gastrointestinal, General Health, Primary Care, Lab Equipment
Company Status: Revenue Growth

Company at a Glance
Exalenz Bioscience creates cutting-edge diagnostic and monitoring platforms, which analyze minute changes in a patient’s exhaled breath. Specializing in noninvasive H. pylori and liver function diagnostics, our patented BreathID® technology delivers immediate results with industry leading specificity and sensitivity.

The BreathID platform offers a user-friendly interface and a cost-effective clinical diagnostic solution that can be used in any clinical setting, including office-based practices, hospitals, laboratories and the ICU.

Technology & Product(s)
The BreathID® technology platform answers the long-standing need for fast, convenient and accurate monitoring of functional diseases of the liver and gastrointestinal tract.

BreathID products are designed for ease of use and user-friendly operation. Testing can be performed in the clinic, hospital or in the lab.

The BreathID® Hp and BreathID® Lab are the most innovative next generation Urea Breath Test (UBT) for diagnosing H. pylori infection and for post-treatment monitoring of H. pylori infection. Their technology is based on measuring the parts-per-million changes in the molecular \(^{13}C/^{12}C\) ratio of the patient’s exhaled breath. This is measured before and after the ingestion of a low dosage of \(^{13}C\) labeled urea dissolved in water. The test is non-radioactive and completely safe. Within 10~15 minutes the real-time analysis is complete and results are available immediately. These results can easily be uploaded into the patient’s EMR.

Goals
Objectives: Locate local distributors.
Target Businesses: Clinics, Hospitals and Labs.
Target Countries: Europe and Latin America.
Flight Medical

Category: Medical Devices
Sub-Category: Medical Equipment
Therapeutic Area(s): Respiratory, EMS - Emergency Medicine Services, ICU - Intensive Care Unit, Primary Care, Pulmonary
Company Status: Revenue Growth

Company at a Glance

Established in 1996, Flight Medical is a part of publicly traded Ilex group (TLV:ILX). Flight Medical is vertically integrated medical device company specializes in the development, manufacturing and marketing of high-end versatile ventilators.

For the last 20 years Flight Medical acquired unique experience in mechanical ventilation working with customers all over the world. Well-known portable ventilator HT50* sold and supported by Newport (Covidien/Medtronic) was developed and manufactured using Flight Medical technology.

Today, Flight Medical operates in 50 countries and won its reputation as truly reliable partner in ventilation. New generation of Flight Medical ventilators, the Flight 60 (F60) - state of the art ventilators provides ICU quality affordable ventilation whenever is needed.

In recent years, over 20,000 ventilators were deployed worldwide for use in ICU, Step down units, Emergency Room (ER), Transport environment (ambulance, helicopters, airplane, etc. FAA approved), Homecare and Long term institutes (Nursing homes).

Flight Medical ventilators are reliable, easy to use, functionality rich and highly affordable ventilators. The Flight60 series is the most versatile autonomous ventilator in the market.

Technology & Product(s)

Flight 60 is a Turbine - based mechanical ventilator designed to address the growing need for ventilation in hospital, long term care, emergency, in-hospital transport, home care and sub-acute. The Flight 60 ventilator is cost effective and offers outstanding clinical performance in a compact and lightweight design. Our ventilators offer advanced ventilation modes, advanced monitoring, easy to use, have invasive and non-invasive capabilities, and unique double battery concept with a total of up to 8-hours battery life (hot swappable battery).

Flight 60 features:
ICU quality in a 5.5Kg ventilator – Flight 60 with advanced modes B-LEV (Bi-Phasic, APRV) and VG (Vt Guarantee - AVAPS/ MV Guarantee) maintain ICU level of care even during transport.
Pressure/Volume Control – Pressure/Flow triggers: whatever the patient situation is, the F60 will adapt to the patient' needs and capabilities to achieve the most natural breathing.
Acute NIV – Flight 60 Turbine ventilator provides up to 60lpm leak compensation with 220lpm maximum flow for excellent NIV performance.
Internal O2 Mixer: High Pressure/ Low flow Oxygen ports to provide Oxygen in any venue/situation
Integrated Nebulizer Port - Synchronized and volume compensated nebulizer port provides excellent patient’s safety.
Ventoux: Ventoux™ is Flight Medical’s newest ventilator series, delivering ICU quality performance to neonatal, Pediatric and adult patients.

Goals

Objectives: Nourish and develop strategic partnerships (such as OEM and technology transfer), in addition to establishing a global distribution network.
Target Businesses: Set worldwide distribution channels for our ventilators in hospitals, home care, transport and long-term care market segments. Develop strategic partnerships on commercial and technological levels.
Target Countries: Worldwide.
GlucoMe Ltd.

**Category:** Medical Devices, Healthcare IT  
**Sub-Category:** Diagnostic & Monitoring, Telemedicine, mHealth, Decision Support System  
**Therapeutic Area(s):** Endocrinology, Diabetics  
**Company Status:** Initial Revenues

### Company at a Glance

GlucoMe is a comprehensive digital diabetes care platform that simplifies the way medical professionals, patients and caregivers manage diabetes.

Glucose measurements and insulin intake are automatically recorded by patient’s smartphone, and saved in the cloud. GlucoMe’s personalized reports, actionable insights, real-time alerts and proactive treatment approach help medical professionals, patients and caregivers ensure compliance, optimize diabetes management and impact overall quality of life.

GlucoMe’s Digital Diabetes Clinic integrates with EHR and continuously analyzes clinical data, providing treatment recommendations for each patient. Along with population management, GlucoMe enables digital or face-to-face intervention for the right patients at the right time.

GlucoMe is CE certified and expects FDA clearance in 2017. It has 9 patents pending worldwide and conforms with ISO 15197:2013.

### Technology & Product(s)

**GlucoMe™ Blood Glucose Monitor**

The wireless GlucoMe Blood Glucose Monitor measures and seamlessly communicates blood glucose data to any iOS or Android mobile device. With no wires or complex communication protocols, reliable ongoing health information is immediately available via the GlucoMe Mobile App and the cloud-based Digital Diabetes Clinic.

**GlucoMe™ Insulin Pen Monitor**

The wireless GlucoMe Insulin Pen Monitor turns any insulin pen into an automatic intake monitor. For all leading insulin pen brands, GlucoMe automatically transfers insulin intake information to any iOS or Android mobile device, and ensures safe data storage on the cloud.

**GlucoMe™ Mobile App**

The GlucoMe Mobile App collects clinical information automatically from the GlucoMe Blood Glucose Monitor and Insulin Pen Monitor, securely transmits it in real time for cloud-based analysis. Personalized and smart insights, along with guidance from medical professionals, ensure effective treatment and reinforce healthy self-care behavior.

**GlucoMe™ Digital Diabetes Clinic (DDC)**

GlucoMe DDC delivers a new level of patient communication and treatment decision support. Leveraging highly accurate, real-time data gathered directly from each patient’s smarthone and analyzed by advanced algorithms, GlucoMe DDC enables medical professionals to remotely monitor patient condition, adjust treatment plans and send professional recommendations directly to patients.

### Goals

**Objectives:** Find business and strategic partners.  
**Target Businesses:** Distributors, telemedicine providers, healthcare providers.  
**Target Countries:** Worldwide.
Gordian Surgical Ltd.

**Category:** Medical Devices
**Sub-Category:** Medical Equipment, Disposable & Implantable, MIS – Minimally Invasive System
**Therapeutic Area(s):** Obesity, General Surgery, Urology, Gynecology
**Company Status:** Revenue growth

---

**Company at a Glance**

Gordian Surgical Ltd. has developed & markets the TroClose1200™ – an integrated port closure system offering surgeons a simple, secure and safe solution to open and suture close the abdominal wall during laparoscopic (minimally invasive) procedures.

TroClose1200 has been successfully used in nearly 200 patients globally including the United States, Europe & Latin America. Gordian Surgical retains the CE Mark & US FDA regulatory clearance.

Worldwide commercialization was initiated during Q3 of 2017.

---

**Technology & Product(s)**

**Technology:**

There is an estimated 10 million laparoscopic procedures performed annually Worldwide. While laparoscopic surgeries are less invasive, closing abdominal access ports remains a difficult and time-consuming task. Today, surgeons manually close the ports with sutures, adding up to 20 minutes per operation. There are surgeons who use a dedicated closure device, as opposed to a simple suture, adding significantly to procedure cost and presenting safety problems.

**Product:**

The TroClose1200 is an integrated port closure system that offers surgeons a simple, secure and safe solution to open and suture close the abdominal wall during laparoscopic procedures. Instead of insertion of closure sutures into the fascia at the end of a procedure, Gordian’s uniquely designed “two in one” obturator & cannula efficiently inserts absorbable sutures into the peritoneal tissue surrounding the cannula at the beginning of the procedure. Two absorbable anchors keep the suture in place. When the cannula is removed, the surgeon closes the fascia by simply tying the TroClose1200 sutures together.

---

**Goals**

**Objectives:** Identify potential partners and distributors.

**Target Businesses:** Similar companies and distributors.

**Target Countries:** Worldwide.
Guide In Medical

Category: Medical Devices
Sub-Category: Disposables & Implantable, Endoscope and Accessories
Therapeutic Area(s): Respiratory, EMS - Emergency Medicine Services, ICU - Intensive Care Unit, General Surgery
Company Status: Regulatory Approval, Clinical Trials

Company at a Glance

Guide In Medical is a medical device company specializing in the respiratory field. The company has developed a novel groundbreaking non-invasive guided intubation device. Our device enables clear identification of the trachea, as well as fast, accurate and safe intubations even in the most difficult clinical scenarios in which visualization of the trachea is very limited.

The company is ISO 13485 certified and received the CE Mark while FDA market approval is expected towards the end of 2017.

The company is seeking for collaboration with distributors and strategic partners.

Technology & Product(s)

Guide In Medical’s guided intubation device is based on a non-invasive electronic illumination patch, which is placed on the patient’s neck.

Once activated, the device transmits signal to the underlying tissues. The signal is completely absorbed by the surrounding tissues, while a fraction of it is emitted solely by the trachea, thus enabling the clear identification of its position during intubations procedures.

Video laryngoscopes, which are capable of detecting the emitted signal, are used to guide the insertion of the ETT into the trachea.

The Guide In device is disposable, one time use and is uniquely capable of transforming ordinary video intubation devices into guided devices, thus facilitating intubation even in the most difficult clinical scenarios.

Goals

Objectives: Finding partners, distributors and suppliers.
Target Businesses: Hospitals, distributors, partners and suppliers.
Target Countries: EU, USA, Canada, Asia (China and Japan).
HealthWatch

**Category:** Medical Devices, Healthcare IT  
**Sub-Category:** Diagnostic & Monitoring, Telemedicine  
**Therapeutic Area(s):** Cardiovascular, Respiratory, General Health  
**Company Status:** Initial Revenues

---

**Company at a Glance**

HealthWatch Ltd. is a medical device company, dedicated to developing next generation wearable monitoring solutions, designed to enhance personal safety and reduce risk for general care patients. Using emerging connectivity technologies, the products seamlessly and transparently secure personal health around the clock, to immediately notify both patients and medical professionals when an emergency is sensed. HealthWatch’s innovative continuous monitoring systems represent a breakthrough in wearable heart-sensing textile electrodes technology (3–12 lead ECG) – all integrated into easy-to-wear everyday garments, enabling early detection of patient deterioration, inside or outside the hospital.

**Market Potential:** HealthWatch’s solutions offer exciting new revenue streams, with total available market potential of more than $35B. Our patented platform technology has wide market application. The company initially targets the cardiac market, supporting in- and out-patient monitoring, preventive medicine, patient follow-up programs and homecare telemetry. Future applications will provide safer and more comprehensive monitoring of active elderly, pregnant women, and first responders. Caregivers can now effectively monitor patients remotely, while reducing hospital readmission rates and cost of care.

---

**Technology & Product(s)**

- **Sensing:** HealthWatch’s MasterCaution® is a heart-sensing seamless garment, featuring embedded digital textile electrodes, for continuous vital sign monitoring, allowing comfort and complete freedom of movement. The MasterCaution® Garment is ideal for use in hospitals, post heart attack patients at home, or for health and peace-of-mind – all without adhesives or skin preparations. The MasterCaution® Garment is machine-washable, with 3–12 lead ECG and other bio-signals, such as activity, motion, falls and respiration.

- **Alerting:** the MasterCaution® monitor and control device is connected to the MasterCaution® Garment, and stored in its side pocket. The MasterCaution® Device utilizes sophisticated signal processing algorithms, accurately analyzing the wearer’s vital signs in real-time, as well as indicating trends over time. Processed data of actual ECG signals, cardiac events such as arrhythmias and ischemia, respiratory abnormalities, sudden patient falls or lack of motion – is wirelessly sent to the wearer’s smartphone or tablet and transmitted to the Cloud. Automatic alerts are then dispatched to assigned medical professionals and standard telemetry or remote monitoring services. MasterCaution®’s delivery of actionable data in near real-time, empower both patients and caregivers, enabling early identification of severe conditions, before they become life-threatening.

---

**Goals**

**Objectives:** Sales, Strategic Partnerships, Distributors.  
**Target Businesses:** Medical Distributors and Service Tele-Monitoring Companies.  
**Target Countries:** Worldwide.
Hip Hope Technologies

Category: Medical Device
Sub-Category: Medical Equipment, Diagnostic & Monitoring
Therapeutic Area(s): Orthopedic, Rehabilitation
Company Status: Initial Revenues

Company at a Glance

Hip Hope Technologies Ltd. (HHT) is the developer and manufacturer of Hip Hope™ smart wearable hip protector device. The device, shaped as a belt and worn around the waist, over the clothes, is intended to reduce fall impacts causing hip fractures in seniors suffering from conditions such as low bone density (osteoporosis) and loss of balance related fall events.

Hip fracture is the common most severe fall-related fracture among elderly people, associated with extremely high rates of mortality, morbidity and loss of independent mobility.

Hip Hope™ is the first active hip protector in the market. First product units have been sold and deployed in Israel, Switzerland and Canada.

Hip Hope™ incorporates a groundbreaking fall detection system, comprising a unique set of sensors. Once an inevitable collision with ground surface is detected, the system instantly deploys two large-size airbags that radically attenuate fall impact. The device provides additional added-value functionalities, such as: Automatic fall alert notification to caregivers, ongoing device status and wearer activity monitoring and built-in emergency alert button.

HHT teamed up with leading medical centres, in performing field research and testing of the device. Hip Hope™ is FDA registered and obtained CE-mark, Health-Canada and AMAR certification.

Technology & Product(s)

Hip-Hope™ is a smart wearable device implementing groundbreaking technology. A fall detection system, combining inertial sensors and proximity laser sensors, activates inflatable airbags, once an impending collision with ground surface is detected. The large-size airbags wrap the hips and reduce the likelihood of impact-related injuries. Official Lab tests have demonstrated 90% impact peak force reduction to the hip. Hip-Hope™ employs state-of-the-art technologies in diverse fields, such as electronics, optics and pneumatics. The product's inventive set of sensors, system logic and algorithm make it possible to reliably distinguish between real falls and misleading fall-like events. Major effort has been invested in achieving senior-compliant design goals, such as wearing convenience, user friendliness and automated operation, in order to secure user adoption and compliance. Hip-Hope™ provides the users and their caregivers with significant daily added-value functionalities, such as: Automatic fall alert notification to multiple caregivers, ongoing device status and wearer activity monitoring and built-in user-operated emergency alert button.

Goals

Objectives: Introduction to potential business partners.

Target Businesses: Orthopaedic, rehabilitation, mobility aid & safety product manufacturers and distributors.
- Medical centers, Hospitals, Rehabilitation centers and Rehabilitation clinics
- Remote activity monitoring and Telemedicine providers
- Emergency alert system providers
- Home healthcare providers
- Chains of Elderly care facilities

Target Countries: We aim at the global market, and in particular – Western Europe and North America.
Hygimed by Maabarot & Ashylon

Category: Medical Devices
Sub-Category: Disposable & Implantable
Therapeutic Area(s): General Health
Company Status: Initial Revenues

Company at a Glance
Maabarot was founded in 1981 and belongs to Kibbutz Maabarot Group, located in Israel. Ashylon is the marketing worldwide distribution.

Maabarot is a leading machinery solutions provider with over 30 years of experience in providing unique solutions for complex challenges.

Maabarot specializes in design and Manufacture of industrial machines in compliance with clients requirements. Ashylon & Maabarot have a joint venture for developing, design and distribute on site HYGI MED medical waste machines, based on a shredder and chemical disinfectant.

Technology & Product(s)

HYGI MED is a shredder with environmental friendly disinfectant at hospital site closest to generation of waste eliminating risks associated with hazardous waste managing and reducing operational costs. Hygimed machine combines environmental friendly disinfectant with strong and effective shredding process, ended by 90% volume reduction of disinfected waste. The disinfecting solution is applied simultaneously in every cycle. Each cycle lasts about 15 minutes for 80 liters of waste. The simultaneous shredding and disinfecting assures direct contact between all parts of the waste and the disinfecting solution allows destruction of the pathogenic biological elements.

Maabarot was founded in 1981 and belongs to Kibbutz Maabarot Group, located in Israel.

Abilities:
Maabarot is a leading machinery solutions provider with over 30 years of experience in providing unique solutions for complex challenges.

Maabarot specializes in design and Manufacture of industrial machines in compliance with clients requirements, integrating knowledge and experience for creative and advanced solutions. The products are a combination of various fields such as mechanical engineering, ergonomics, automation, materials engineering, electronics, and control systems.

We offer full response through preliminary concept, development, design, manufacture, installation, and maintenance.

We provide full solution to client’s requirements, reliability, initiative, dynamic and creative thinking to push forward the industry as a whole along with our company.

Ashylon & Maabarot have a joint venture for developing, design and distribute on site HYGI MED medical waste machines based on a shredder to reduce volumes up to 90% and a chemical disinfectant compliance with STAAT 3 standard. The Hygimed Machines are very simple to operate and maintain and makes redundant the need of using pollute methods as incinerators or land fil.

Goals

Objectives: Looking for distributors all over the world.
Target Businesses: Looking for distributors all over the world.
Target Countries: Europe, South Africa, US, Asia.
IceCure Medical Ltd.

**Category:** Medical Devices  
**Sub-Category:** MIS – Minimally Invasive System  
**Therapeutic Area(s):** Women’s Health, Oncology  
**Company Status:** Initial Revenues

---

**Company at a Glance**

IceCure Medical is an Israeli company that develops and markets minimally invasive cryoablation therapies for women’s health and other areas. Our proprietary IceSense3™ system provides minimally invasive, in-office definitive treatment for breast tumors, both benign and breast cancer [1].

IceCure sells its products in the U.S (both direct and by distributors through its subsidiary IceCure Medical, Inc. having its office in Memphis, Tennessee). Among our U.S clients are breast centers in reputable institutions as well as private clinics operated by breast surgeons and radiologists. In other geographies, IceCure uses specialized distributors that provide clinical and technical sales support in Asia and Europe.

IceCure has FDA and CE approval for broad benign and malignant indications. The company is also in advanced regulatory process in China with the CFDA (Console/Machine already approved 6/2016 – single use probes in process) as well as other Asian and South American countries.

Thanks to its unique and innovative technology, IceCure participate in several clinical studies for treatment of other indications such as lung cancer, Kidney cancer and breast cancer. The company also develops a product for treating uterine fibroids.

With the global trend of taking procedures from the operating room to the office environment and decreasing their costs, IceCure’s innovation brings the future to the present!


---

**Technology & Product(s)**

Cryoblation is a minimally-invasive ultrasound /CT guided treatment that uses extreme cold to freeze and accurately destroy diseased tissue within the tumor zone. The ablated tumor becomes necrotic and as such, shrinks and absorbed by the immune system. Cryoablation exists more than 2 decades and has been successfully used in various application based on slow, gas-based technology. IceCure uses liquid-Nitrogen based technology which is more compact, faster and more efficient.

IceCure sells the IceSense3™ system in the U.S since mid-2011 for the treatment of benign breast tumors under CPT code 19105, with support of the American Society of Breast Surgeons (ASBS). Recently, clinical results from a study of treatment of small breast cancer tumors were published, showing no cancer recurrence after follow-up period of up to 6 years. IceCure intends to continue with more U.S and international studies in this promising direction.

The procedure is a safe and effective treatment option that has the following characteristics:

- Performed by one physician
- An office procedure
- Local anesthesia
- Can be completed in 5–15 minutes
- No pain
- No scar
- Superior cosmetic results
- Short recovery time


---

**Goals**

**Objectives:** Expand sales in Europe, Asia and other countries, use platform to enter new areas.

**Target Businesses:** Women’s health, interventional oncology, general surgery.

**Target Countries:** On top of the U.S, Europe, China, India, Latin America.
Inovytec Medical Solutions Ltd.

Category: Medical devices, Healthcare IT  
Sub-Category: Medical Equipment, Telemedicine  
Therapeutic Area(s): EMS – Emergency Medicine Services, Cardiovascular, Respiratory  
Company Status: Initial Revenues

Company at a Glance

Inovytec Medical Solutions Ltd. (“Inovytec”) specializes in cutting-edge technologies for medical emergencies’ first-line solutions, particularly for respiratory and cardiac critical aid. Inovytec products are designed to save lives where the first few minutes are crucial and dramatically affect patient’s outcome. Inovytec’s vision is to provide efficient live-saving devices for use by any first-responders, Anytime. Anywhere.

Inovytec is led by a team of highly-experienced executives and R&D engineers, and supported by internationally-recognized experts in emergency medicine, intensive care and cardiology.

Technology & Product(s)

Our devices:

The Lubo™ is a single-use, non-invasive airway device which imitates mechanically the well known ‘Jaw-Thrust’ maneuver. Lubo allows any first responder to manage airway by a simple and easy to use device.

In addition, the Lubo allows neck-free immobilization contributing to airway management in patients suspected of cervical spine injury. Lubo allows immobilizing the cervical spine in trauma cases, without pressure on the carotid and jugular veins and without increasing the ICP (Intracranial pressure) in the skull. Lubo started sales with CE, FDA, Anvisa, CFDA, TGA, KFDA clearances.

The SALI™ SALI is a new-breed solution for respiratory and cardiac emergencies. It is a full critical first aid solution that creates a virtual hospital environment at the scene and significantly increases the effectiveness of the medical treatment. SALI has CE certification.

The VentWay™ is a family of lightweight (1.1Kg or less) small size mechanical ventilators, designed for out-of-hospital critical care and oxygen therapy in field conditions and during transit. This innovative ventilator perfects the standard of care in military medicine, home care environment and transport medicine. The technology of multi-functionality along with light-weight and portability features, positioning VentWay™ as the optimal solution for various acute respiratory emergencies.

Goals

Objectives: To have Inovytec’s innovative solutions placed in out-of-hospital surrounding and used by first responders in civilian, disaster management and military markets.

Target Businesses: Strategic distributors and partners.

Target Countries: Europe, Asia, North America.
Lumenis Ltd.

**Category:** Medical Devices  
**Sub-Category:** Medical Equipment, MIS – Minimally Invasive System  
**Therapeutic Area(s):** ENT – Ear, Nose and Throat, Gynecology, Urology  
**Company Status:** Revenue Growth

### Company at a Glance

Lumenis is the world’s largest energy-based medical device company for surgical, ophthalmology and aesthetic solutions. As an international leader in the development and commercialization of innovative energy-based technologies, including laser, Intense Pulsed Light (IPL), Radio-Frequency (RF) and Ultrasound, Lumenis has redefined medical treatments and set numerous technological and clinical gold standards.

Lumenis’ vision is to provide better technology for better patient care through innovative energy-based solutions. With a ground-breaking technological legacy of more than 50 years, we are committed to enhancing patient health and quality of life; addressing new and growing needs of aging populations; and offering medical professionals innovative solutions to meet the developing and dynamic healthcare environment of the 21st century.

Lumenis operates in three core markets: Surgical, Ophthalmology and Aesthetics. Throughout our history, Lumenis has created innovative solutions for previously untreatable conditions and designed advanced technologies that have revolutionized existing treatment methods in each and every one of the sectors we operate in.

With more than 20 new products launched since 2010 and multiple new applications in the pipeline, Lumenis is poised to maintain and grow our leadership position, bringing our advanced technological innovations to patients all over the globe.

### Technology & Product(s)

We pioneered the development of high-powered holmium lasers for the urology application, including the HoLEP procedure for the minimally invasive treatment of benign prostatic hyperplasia (BPH), and urinary lithotripsy. HoLEP, the use of our high-powered holmium laser (the Lumenis Pulse™ 120H) to perform enucleation of the prostate, has proven to be more effective than alternatives while minimizing collateral tissue damage and demonstrating the lowest recurrence rates. In addition, the high-power, high-repetition holmium laser is an effective form of treatment for a broad range of urinary and kidney stones, enabling stone dusting, which reduces the stones to minimally sized particles and allows them to be self-cleared.

Our CO₂ laser-based product line (The UltraPulse® DUO and AcuPulse™ DUO) is a leader in the treatment of benign and malignant lesions and inflammations in the ear, nose and throat (ENT) laser market, using innovative technology, including guidance technology, which provides advanced precision with minimal collateral tissue damage compared to other alternatives. Our CO₂ laser application for vocal chords rescission provides better patient outcomes and lower overall costs to the healthcare system. In Gynecology, Lumenis leads the way, offering smart CO₂ laser solutions providing gynecologists and fertility experts with an ultra-precise and flexible CO₂ laser solution for treatments of endometriosis, uterine fibroids, adhesions and vaginal health-related conditions.

### Goals

**Objectives:** We would like significantly enhance our presence in the Urology, ENT and GYN. clinical areas in any given country in general and in EMEA region in particular.

**Target Businesses:** Distributers, located in EMEA, who are specialized in selling capital systems and disposables products in Urology, ENT and GYN.

**Target Countries:** Any country located within EMEA.
Medasense Biometrics Ltd.

Company at a Glance

Medasense meets the clinical need to objectively assess pain.

Pain affects quality of life for millions of patients. Unmanaged pain delays recovery, increases morbidity and mortality, and overburdens healthcare resources.

There are currently no clinically accepted tools to objectively assess pain. Clinicians must rely on patients’ subjective assessments, or simply guess when patients can’t communicate.

Medasense’s breakthrough NOL™ (Nociception Level) Technology, is the only pain assessment index based on dozens of pain-related physiological parameters and clinically validated as superior to other nociception/pain indicators. The patented platform technology is based on artificial intelligence algorithms and signal processing. It enables objective, non-invasive, and continuous assessment and monitoring of the physiological response to pain.

Technology & Product(s)

Medasense’s flagship product is PMD-200™: an intraoperative pain monitoring system.

Based on the patented NOL™ technology, the PMD-200 provides objective, non-invasive, and continuous monitoring of the physiological response to pain.

The need: During general anesthesia, a patient’s body reacts to painful stimuli – although it is not consciously recognized. This intraoperative pain can stress the patient’s body and worsen pain after surgery. As the patient cannot communicate it is hard for clinicians to evaluate. Consequently, the patient may be given insufficient analgesia, which can promote postoperative pain, or excessive analgesia which can result in overdosing and related complications.

The solution: By using the PMD-200™ in operating rooms, for patients under general anesthesia, clinicians are able to assess nociception, and titrate analgesic medications – avoiding excessive use or underuse that may result in significant complications.

PMD-200™ is a simple to use, stand-alone monitor.

How it works: Medasense’s technology combines a non-invasive sensing unit and a monitor:

Sensing – a non-invasive finger probe continuously acquires pain-related physiological signals through four sensors.

Analyzing – artificial intelligence algorithms and signal processing identify and analyze changes in pain-related physiological patterns.

Grading – the information is presented on the PMD-200™ bedside monitor as a real time, personalized index – the NOL™ (Nociception level) index that varies from 0 (no pain) to 100 (extreme pain).

Goals

Objectives: Launch of PMD-200 pain monitoring system for operating rooms. Target OEM collaborations and strategic partnerships. Target distributors.

Target Businesses: OEM, Distributors, Hospitals and Health Insurances.

Target Countries: Czech Republic, Baltics, Japan, South Korea, Slovenia, Hungary, Russia, Thailand, Mexico, Brazil, Turkey, South Africa.
Company at a Glance
Since its establishment in 1995, Medisim has become a leading and innovative force in developing top-class non-invasive Professional and Home Thermometry products and is known for its property know-how of core body temperature establishment.

Professional Thermometry product line include Temple Touch Pro system (TTP™). It is a dependable, non-invasive continues temperature monitoring system for Hospital use. The TTP™ system was clinically substantiated as accurate and reliable, offering a state of the art, yet cost-effective solution for multiple clinical environments.

Home thermometry products offer non-invasive measurement with accuracy, speed and reliability, for ultimate comfort, used for the entire family, including infants.

Technology & Product(s)
From home and family care to professional hospital solutions, Medisim brings its technology expertise and innovative capabilities.

TTP™-Core Temperature Monitoring & Analysis
Core temperature monitoring & management are a vital tool in prevention, diagnosis, and treatment of patient complications. Temple Touch Pro™ is an accurate, reliable noninvasive core temperature system which is operational during patient alertness or under any anesthesia type. Based on unique conductive heat flux technology, TTP™ offers a state of the art yet cost-effective temperature monitoring solution for multiple clinical environments (the operating room, post anesthesia care units and intensive care units).

TTP™ continuously transmits real time, accurate core temperature data to the patient monitor.

Advanced Home Thermometry
Home thermometers must be accurate, quick and simple to use, especially in the case of infants. Inspired by family needs, Medisim has developed a wide variety of advanced thermometers, designed for different temperature-taking formats to ensure the user’s comfort. Medisim is renowned for its expertise in the field of thermometry; its devices are easy to use, providing swift, accurate results for all family members including infants.

Goals
Objectives: Finding partners and distributors.
Target businesses: Distributors and Hospitals.
Target Countries: Europe, USA.
Medispec Ltd.

Category: Medical Devices
Sub-Category: Medical Equipment
Therapeutic Area(s): Cardiovascular, Nephrology, Orthopedic, Urology, Veterinary, Wound Management
Company Status: Revenue Growth

Company at a Glance

With over 25 years of experience and expertise in shockwave therapy solutions, Medispec continuously introduces competitive systems and technological breakthroughs to the market. The company specializes in shockwave-based systems for urology, cardiovascular and orthopedics applications. Medispec services clinics, medical centers and hospitals in over 80 countries worldwide. All of the company's systems offer modular design, versatility, ease of use and high degree of mobility, for delivering innovative technology in a fast and efficient manner.

We aspire to bring the opportunity to heal wherever it is needed. Our professional team continuously innovates and explores new medical applications where shockwave therapy can be used to heal and better people’s lives across the globe.

Technology & Product(s)

Shockwave therapy offers an alternative to surgery and its undesirable side effects. We offer non-invasive treatment with proven high success rates, as well as drugs-free and painless treatment at short treatment time.

Our flagship device- ED1000- offers gold standard treatment for Erectile Dysfunction.

Erectile Dysfunction Shock Wave Therapy (EDSWT) is an innovative approach to vasculogenic ED, using advanced acoustics technology.

EDSWT utilizes low-intensity extracorporeal shock waves, focusing on blood vessels and encouraging neovascularization in the penis shaft and crus. The low-intensity shock waves help relieve vascular deficiency, a common cause of erectile dysfunction.

The shock wave treatment causes no side-effects or systemic load on other organs and healthy tissues. This non-invasive, painless EDSWT procedure is performed during a series of brief visits to the urology office, and requires no sedation or anesthesia.

Cardiospec- New non-invasive therapy approach using Extracorporeal Shockwave for Myocardial Revascularization (ESMR) offers non-invasive therapy, clinically proven and safe procedure, which stimulates the formation of collateral blood vessels in ischemic heart tissue, enhances blood perfusion and restores cardiac function. Cardiospec is the only system in the market offering the largest focal zone and a unique precision ultrasound probe enabling accurate targeting.

Goals

Objectives: Expanding our business partners and distributors.
Target Businesses: To expend our distributors channels, as well as hospitals and medical centers.
Target Countries: Germany, Switzerland, Austria, Belgium, Sweden, Slovakia, Hungary, Romania, Bulgaria, Poland, Czech, Ukraine, Russia, Baltics, India, China, S. Korea, Thailand, Vietnam, Philippines, Hong Kong, Turkey, S. Africa.
MediTouch

**Company at a Glance**

MediTouch was established in 2004 with the aim of developing and distributing innovative physical rehabilitation solutions for hospital, community clinic and home care use.

MediTouch firstly targeted hand rehabilitation indications and launched its HandTutor™ system with CE and FDA certification in 2008. The HandTutor™ system is now used worldwide in major rehabilitation facilities, private occupational and physiotherapist practices and by home care patients.

In 2011 MediTouch launched three new Tutor products. Firstly, the ArmTutor™ allows for evaluation and virtual functional task evaluation of the arm including the shoulder and elbow. Secondly the LegTutor™ was introduced to allow evaluation and virtual functional task treatment of the hip and knee. Finally, the 3DTutor™, a wireless sensor was introduced. The 3DTutor™ can be positioned on several parts of the body and compliments the ArmTutor™ and LegTutor™ to give complete upper and lower extremity evaluation and treatment solutions, including leading TeleRehabilitation services based on the MediTutor™ software.

In 2014 MediTouch launched The BalanceTutor™. Its new technology allows the therapist to create postural perturbation such as a slip or a trip. Its advanced technology utilizes the platform’s movement in a medial/lateral and forward/backward direction while the patient is standing, walking or running allowing customized postural control practice in the specific gait phase that the therapist chooses to focus on. This allows for a vast range of physical therapy indications. It is the only rehabilitation system that employs an advanced 4D perturbation patented treadmill, multiple force and movement sensors and customized motivational video games.

**Technology & Product(s)**

MediTouch develops Physical Rehabilitation Solutions based on hardware, dedicated rehabilitation software and physical rehabilitation clinical know-how. The solution is used by OTs and PTs in rehabilitation clinics both inpatient and outpatient, in community physical and occupational therapy clinics and by home users, worldwide. The MediTouch system uses computerized games enabling the therapist offer the patient more opportunities and environments both at the clinic’s and at home, to practice repetitive functional movements. MediTouch has also introduced a robotic dynamic balance trainer system that uses the proven principle of perturbation. All systems provide capture and recording of the quantitative data concerning the rehabilitation process and allow objective follow up to ensure therapy accountability.

**Goals**

**Objectives:** Establish and support a worldwide distribution network.

**Target Businesses:** Physical Rehabilitation.

**Target Countries:** Worldwide.
Mennen Medical & MTRE

Category: Medical Devices
Sub-Category: Diagnostic & Monitoring
Therapeutic Area(s): ICU - Intensive Care Unit, Cardiovascular, Pediatrics, Neuroscience, General Surgery
Company Status: Revenue Growth

Company at a Glance

Mennen Medical Ltd. is a leader manufacturer in patient monitoring, diagnostic instrumentation, clinical information systems for hospital based cardiac catheterization, thermoregulation solution (TTM and Normothermia) and a non invasive solution for measuring bilirubin in neonates.

Mennen Medical also provides its unique technologies and services to other medical devices manufactures in the form of OEM or private label cooperation.

Fully owned by Mennen medical Group: MTRE specializes in thermoregulation and Gerium Medical specializes in non-invasive transcutaneous Bilirubin measurement.

Technology & Product(s)

1. Targeted Temperature Management - Non-Invasive Cooling and Warming Systems:
   - CritiCool (Therapeutic Hypothermia ICU), CritiCool Pro, Allon (Maintenance of Normothermia – OR), CliniLogger (collecting data during the procedures for studies and maintenance).

   Technology: Fully automatic servo-controlled labor free system, Very precise and stable temperature management (core and surface temp sensors), Tap water based system, Disposable wraps (wide variety of sizes – for all types of patients), Light weight machine (35 Kg), Silent operation, Connectivity to patient monitor (unique in the market), Transport capability (unique in the market)

2. Transcutaneous Bilirubin Meter: Bilicare

3. Cardiac Catheterization: Horizon XVu Hemodynamic System

4. Electrophysiology: EMS–XL System

5. Patient Monitoring Systems: Vitalogik Monitors Series, Central Station, Network Connectivity, Remote Monitor, Modular Patient Monitor, Dual Channel EEG and aEEG.

   Technology: Display all Vital Signs, Non Invasive Model includes: HR/Resp/SpO2/NIBP/Temp, Invasive Model provides additional parameters: 2/4 BP, CO, Customizable to meet the user’s needs, Connectivity between bedside monitors, HIS, LIS and WEB access.

Goals

Objectives: B2B Opportunities.

Target Businesses: Distributors and OEM Companies.

Target Countries: Worldwide.
Meditrac Ltd.

**Category:** Medical Devices  
**Sub-Category:** Medical Equipment  
**Therapeutic Area(s):** Orthopedic  
**Company Status:** Revenue Growth

### Company at a Glance

Meditrac is the manufacturer of the only 3D portable decompression devices for back and neck pain. Coupled with our proprietary treatment concept, “Traction on the Move”, Meditrac encourages patients to be physically active while receiving decompression to the spine.

With more than 20 years in the market and above 85% recovery rate, Meditrac decompression units are an alternative to surgery to thousands of patients.

**Now expanding globally we are looking for sales representatives and regional distributor to join our family!**

### Technology & Product(s)

Developed by a team of orthopedic surgeons, Meditrac’s solution combines the benefits of portable decompression therapy with freedom of movement to deliver immediate pain relief and rehabilitation.

Meditrac products are intelligently designed to outperform traditional traction devices, braces and decompression tables using 3 Dimensional decompression: vertical, horizontal, symmetrical and asymmetrical, allowing for complete freedom of movement during treatment.

This allows patients active rehabilitation treatment that effectively increases blood circulation to the injured area, allowing for an accelerated healing process.

More than 85% recovery rate is reached within two weeks of 15-to-30 minute daily treatment sessions.

**Meditrac now offers healthcare professionals, clinics and wellness centers to join our new Partner Program.**

Our program has three main goals:

1. Generate a new growth channel for our partners through dedicated marketing campaigns
2. Attract more clients to partners’ clinics for either a full treatment program or a onetime adjustment/training session
3. Promote Meditrac’s products for home care use, with higher clinical outcomes

**Main benefits:**
- Practice growth
- High patient satisfaction
- >85% recovery rate
- Short 15-30 minute treatment session
- Ability to treat patients simultaneously
- Do not occupy any floor space
- No power source required
- Maintenance-free
- One size fits all
- Produced with finest quality materials

### Goals

**Objectives:** We are looking for regional distributors and sales representatives.

**Target Businesses:** Distributors, Sales representatives, manufacturers’ representatives, Orthopedic Centers, physical therapy & rehabilitation centers.

**Target Countries:** Spain, Portugal, Italy, Germany, Korea, China, USA, Asia & South Africa.
Mizra Medical

Category: Medical Devices
Sub-Category: Medical Equipment, Disposable & Implantable, OTC – Over the Counter
Therapeutic Area(s): General Health, Urology, Orthopedic, Pediatrics, ENT – Ear, Nose and Throat
Company Status: Revenue Growth

Company at a Glance

Mizra Medical is a manufacturer of High quality dip latex products, Medical disposable products, male external catheter, urology accessories products, Monofiliment test, Developing new produces, ISO 9001 13485 CE FDA certified. We welcome OEM. Mizra Medical provide High quality products and service

Technology & Product(s)

High quality dip latex products, Medical disposable products, male external catheter, urology accessories products, Monofiliment test, Developing new produces, ISO 9001, 13485, CE FDA certified.

Goals

Objectives: Contact with decision makers, Distributors, hospitals, OEM.
Target Businesses: Distributors, hospitals, OEM.
Target Countries: All countries.
NanoVibronix Ltd.

Category: Medical Devices  
Sub-Category: Medical Equipment  
Therapeutic Area(s): Infection Control, Urology, Wound Management  
Company Status: Revenue Growth

Company at a Glance

NanoVibronix is a medical device company that seeks to fulfill selected, significant unmet medical needs in the therapeutic areas of pain, wound and soft tissue healing and in the area of catheter related infection and injury.

NanoVibronix Ltd, is located in Nesher, Israel and performs research and development as well as manufacturing and marketing of the company's products. NanoVibronix Ltd. is a subsidiary of NanoVibronix Inc. which is located in Elmsford, NY. The company is publicly traded in NASDAQ (NAOV).

Technology & Product(s)

NanoVibronix’s technology consists of a unique, miniature transducer technology that transmits low-frequency, low-intensity ultrasound onto treatment surface. These transducers are small, thin (1mm), flexible, lightweight (5g), and create Surface Acoustic Waves reaching up to 10 cm from the transducer. These operating parameters allow the creation of a small, self-adhering acoustic patch that contains the transducer and administers the ultrasound. This application revolutionizes the way administration of low-frequency, low-intensity ultrasound for therapeutic clinical applications by eliminating the need for technicians and medical personnel to manually administer ultrasound therapy using large transducers, encouraging patient independence, promoting clinician supervised home based care and reducing the cost of therapy. Applications using this technology include wound treatment, soft tissue healing and pain treatment.

The technology allows converting indwelling catheters into active acoustic disease-fighting devices. Certain catheters often pose a risk of biofilm and infection as well as a risk of trauma and discomfort. NanoVibronix devices attached to catheters reduce catheter-associated infection, antibiotic usage and bacterial resistance and therapeutically treat catheter-associated injury.

**PainShield™** - ultrasound therapy for pain relief, soft tissue healing and non-union fractures.

**UroShield™** - prevents biofilm formation on urinary catheters to decrease risk for UTI, increases antibiotic efficacy and decreases pain and discomfort associated with urinary catheter use.

**WoundShield™** - accelerates healing of chronic and acute wounds

Goals

**Objectives:** Expand distribution network.

**Target Businesses:** Hospitals, Nursing homes, clinics, home-care.

**Target Countries:** Germany, France, Spain, Scandinavia, Asia and S. America.
neoLaser

Company at a Glance

NeoLaser designs, manufactures and distributes medical laser products, offering top-notch quality and world-class design, providing superb performance and functionality, flexibility and modularity, all at an affordable cost. neoLaser’s products support a variety of high volume applications including Vascular, Proctology, Spine/PLDD, ENT and endoscopic surgery as well as Aesthetic procedures. Founded by seasoned veterans of the medical laser industry, neoLaser brings the highest engineering, marketing and design knowledge. Quality is the focus of our company and products. From component selection, through work processes, to final thorough inspection, neoLaser takes great care to ensure that our products will conform to the most stringent quality standards, and strive for continuous improvement.

The company is ISO13485 certified, holds both CE mark and FDA clearance for its high-end medical laser systems. neoLaser is currently in strong revenue growth, a growing global installed base and over 30 distribution partners worldwide. The neoV system is gradually becoming a benchmark of design and clinical excellence and is featured in surgical master classes and courses.

Technology & Product(s)

The neoV Series offers a variety of wavelengths and applications:

The neoV1470 and neoV980, with 12 Watts and 28 Watts of 1470nm and 980nm respectively, offer the latest state of the art unit for Endovascular and Proctology treatments, including unique surgical probes – the CORONA 360, circular emission, the CORONA Fistula Probe and the CORONA Hemorrhoid Probe. In addition, special Orthopedic/PLDD Kits are available for herniated disc treatment, enabling superb results through a minimally invasive surgical technique. In ENT, the neoV980 facilitates a wide variety of surgical interventions, including otology interventions, such as stapedotomy, trans-nasal procedures such as turbinate reduction, polyps, HHT, and also laser assisted tonsillectomy. The neoV1470 enables precise ablation and excision for airway procedures.

Additional applications for neoLaser’s platform include a wide array of aesthetic procedures – laser assisted lipolysis leveraging the unique precision of the neoV1470, nail fungus and wart treatment with the neoV1064, and spider vein coagulation with the powerful neoV980.

neoV – Good Things Come in Small Packages

Wavelength versatility: neoV1470, neoV980, neoV1064
World-class design and high quality cooling technology
Smallest 28Watt system on the market
Affordable Cost, ease of use, portability, and reliability

Goals

Objectives: Growth revenue through build-up of global distribution, OEM partners, and direct sales.

Target Businesses: Distributors and OEM partners in multiple therapeutic areas (Vascular, Proctology, Spine, ENT, Aesthetic).

Target Countries: Global – Europe, USA, Central America, Asia, South America, Africa.

www.neo-laser.com
Noam Urim

Company at a Glance

Noam Urim is one of the largest non-woven needle punch producers in the Middle East. We produce disposable fabrics for the hygiene and medical industry including impregnated fabrics with variety of soaped formulas used for bathing dry soaped sponges, “in line” printing capabilities, antibacterial and cosmetic applications. We also produce absorbent and orthopedics pads raw material/rolls designated for convertors in the medical industry.

Noam Urim supply private label (PL) upon requests. One of our leading PL DiniClean® bathing soft sponges specified for confined to bed patients who can be washed in their bed. (1223/2009/EC).

ScrubbyPetTM, Pet Bath soaped Mitten will be represented first time in the Medica as an easy solution for No-Rinse bath mittens for pets.

Our R&D team works closely with our clients to define and develop the perfect fiber blend for any application. The products are packaged to choice in - mother rolls, bulk packaging or private label packaging. Noam Urim manufactures fast developed, tailor-made articles.

The company is ISO 9001:2000 certified, assuring highest standards of quality for all our products we export worldwide.

Technology & Product(s)

We use needle punch non-woven technology producing tailor made fabrics including:

1. Heavy nonwoven fabrics higher than 90 gsm
2. Develop fabrics based on variety of mixed fibers composition
3. In line impregnation technology
4. Converting capabilities

During the Medica we will be focused on the following items:

1. DiniClean® disposable hygiene bathing dry soft soaped sponges used for bathing patients in their bed or during bathing having all in one item. Save labor cost to the hospitals and nursing homes.

DiniClean® regulated under.(1223/2009/EC) and can be used under other PL as well.

2. ScrubbyPetTM, Pet Bath soaped Mitten will be represented first time in the Medica as an easy solution for No-Rinse bath mittens for pets

3. Absorbent pads for different use in the medical and hygiene industry

4. Variety of cosmetic pads

5. Antibacterial fabrics provide permanent built-in protection against bacterial growth, mold, fungi and yeast, providing long-lasting antibacterial protection that does not wash off.

Goals

Objectives: Find distributors, alliances, clients (converters and private label).

Target Businesses: Medical equipment supply, Hospital disposable, Health centers, Distribution.

Target Countries: Worldwide.
Nuvo Group

Category: Medical Devices, Healthcare IT
Sub-Category: Diagnostic & Monitoring, Decision Support System
Therapeutic Area(s): Gynecology, Obstetrics
Company Status: Pre-Clinical

Company at a Glance

Nuvo is developing a line of medical products that provide powerful alternatives to traditional Doppler/CTG. Our products will provide professionals with a more convenient way to monitor pregnancy health markers of both the mother and fetus both remotely and in in-office settings.

Our focus is on developing wearable, sensor based technologies that utilize big data analytics to provide new insights throughout pregnancy via automatic, continuous, remote, and hassle-free pregnancy monitoring. Our solution is based on the combination of measures of well-established biomarkers including: fetal movement, cardio-vascular activity of mother & fetus, uterine contractions/pulse propagations and maternal activity.

Our products provide powerful alternatives to traditional Doppler/CTG by simultaneously capturing direct information of both mother and fetus using revolutionary passive technologies. Our products use a sophisticated set of passive sensors, seamlessly integrated within a comfortable pregnancy belt, designed to safely and accurately collect and analyze important health data simultaneously from the mother and the fetus – remotely, in real-time – and removes the obstacles to health by providing information and remote access to health providers.

Nuvo is committed to creating new and innovative solutions to the challenges facing maternal care. We are excited about our products and technological advancements and look forward to sharing our progress with the medical community.

Technology & Product(s)

Pregnancy can present a variety of health risks to both expectant mothers and their developing child. Although the risks differ in severity based on age, general health and preexisting conditions, all pregnancies carry some risk. Complications can involve the mother’s health, baby’s health, or both.

PregSense is being developed to simultaneously capture information of both mother and fetus using revolutionary passive monitoring technologies. Our Wearable Sensory Belt is a self-contained, active unit that includes a built-in rechargeable power-source, micro-controller, memory and bi-directional communication channel to a mobile device.

The proposed solution is built for scalability and affordability, allowing each woman to get access to hospital grade technology and maternal health information at a fraction of the cost and time of current conventional methods. Even when far from a health clinic women can still get access to crucial vital health information over their mobile phone, which can improve outcomes by providing early detection and, when needed, early intervention.

The wearable monitoring solution will provide accurate and early diagnosis of fetal distress based on robust, continuous, passive and noninvasive monitoring of fetal and maternal vital signs. Enabling the prediction and prevention of severe complications using smart big data analysis.

Goals

Objectives: Explore Distributer and New Business Partnerships.
Target Businesses: Medical Device Distributors, Hospitals (Large & Small), Clinics, Obstetricians – Providers with Pregnancy Monitoring Needs.
Target Countries: EU (UK, Germany, Italy and Netherlands), USA, Asia (China).
OCON Medical Ltd.

**Category:** Medical Devices  
**Sub-category:** Disposable & Implantable, Drug delivery  
**Therapeutic Area(s):** Women's Health  
**Company Status:** Initial Revenues

---

### Company at a Glance

OCON Medical Ltd. ("OCON") develops next-generation intrauterine drugs-device products based on its proprietary platform – the Intrauterine Ball (IUB™), in a market that has not seen any innovation for the last 3 decades. Founded in early 2011 OCON has since established itself as a leading women’s health (WH) innovator with a proven technology already used by well over 40,000 women.

In the short period of time since established, OCON has accomplished:
- Development and successful obtainment of Class III drug-device product regulatory approval.
- Establishment of a marketing network in Europe with launches that have resulted in over 10% market share within less than a year.
- Proven market acceptability with over 50,000 units sold.
- Establishment of large scale in-house development and manufacturing capabilities.
- Development up to the in-vivo stage of two key pipeline products.
- Being recognized as a top ten intrauterine product innovation company.

With its initial IUB™ Ballerine™ product OCON has proven the concept of successful market acceptance of a new generation of IUD and validates medical utility of a new generation of intrauterine drug device.

### Technology & Product(s)

- **IUB™ Ballerine™** - Non-hormonal long acting reversible contraception (LARC)
- **Sphera™** - Levonorgestrel eluting LARC

- The IUB™ SCu300 product family is a non–serviceable, single use intrauterine implanted long acting reversible contraceptive. The IUB™ is a spherical carrier made of nitinol, a new biocompatible super-elastic alloy used in coronary and neurosurgery stents, which offers ideal intrauterine adaptivity. This allows simpler and safer introduction into the uterus and provides superior adaptability to the uterus’ shape.
- Product currently in development by the company is the Sphera™ is also non–serviceable. The Sphera™ is a long acting reversible hormonal intrauterine contraceptive product based on sustained release of levonorgestrel.
- **Key technologies**
  - The basis for all products of the company is its proprietary three-dimensional frame. This frame is introduced into the uterus in a linear form, loaded in a tube. Once deployed from the tube it obtains its programmed spherical form. The super–elastic characteristic of the frame material enables this property while providing sufficient compliance to provide advantageous physiological compatibility.

### Goals

- **Objectives:** To become a leading women’s health innovator in a field of poor innovation, high unmet needs and sizable market.
- **Target businesses:** Gynecologists, HMO’s.
- **Target Countries:** Europe, LATAM, China, Canada, Australia and eventually US.
Peak Medical

Category: Medical Devices
Sub-Category: Medical Equipment
Therapeutic Area(s): ICU - Intensive Care Unit
Company Status: Initial Revenues

Company at a Glance

Peak Medical is a private company established in 2012. The Company develops and manufactures special innovative products for EMS, airway management, intensive care and respiratory support.

Companies have developed and continue to develop number of products for resuscitation of neonates and especially for preemies with extremely low weight. All the products do beyond what traditional devices would normally supply. All of them are based on own patents.

Most of the products are CE certificated. Peak Medical is FDA registered manufacturer.

Technology & Product(s)

- Plastics, electronics, video systems, precision mechanics, 3D printing
- Laryngoscopes, Video laryngoscope, Special Guides, Resuscitators

Goals

- Objectives: Mass Production + license transfer.
- Target Businesses: Development.
- Target Countries: EU, USA, Korea, Japan.
Pharma Sept Ltd.

**Category:** Medical Devices, Others  
**Sub-Category:** Disposable & Implantable, Industrial Use, OEM  
**Therapeutic Area(s):** ENT – Ear, Nose and Throat, General Surgery, Neurology, Orthopedic  
**Company Status:** Revenue Growth

---

**Company at a Glance**

Pharma Sept brings to the market high-quality surgical covers and drapes that eliminate the risk of patient cross contamination and keep surgical equipment downtime to a minimum.

With more than 20 years of experience as a leading manufacturer, we have developed disposable surgical products, which are used by the finest medical institutions.

Our products help keep operating rooms sterile, equipment clean, and patients safe from contamination. Our flexibility ensures that we can accommodate special needs and our commitment to our customers is our trademark.

Pharma Sept products are innovative and easy-to-use, which meet the international quality standards of contamination prevention.

Loyal customers, many of whom have been working with us for decades, attest to the value of our products, the quality of our designs, and the strength of our commitment.

Pharma Sept continues to grow as a company and always seeks new partners interested in representing and selling our products.

---

**Technology & Product(s)**

Pharma Sept Ltd. has developed a comprehensive line of products which provide perfect solutions for the demanding market of hospital operating rooms. Our focus is on Microscope, C-arm and general equipment covers, Ultrasound probe covers and more. Pharma Sept’s production line starts with raw materials and ends with finished product this gives us the flexibility to adapt our products to the customer’s specific requirements.

By using only the highest quality raw materials, we ensure that our drapes are the finest on the market.

We also offer a wide range of packaging options, which can be tailored to the customer’s needs: single or double packed, sterilized, non sterile or bulk.

Pharma Sept is a well known brand and also provides OEM services to leading international companies. We are CE certified and FDA approved, employing 120 highly skilled professionals.

Pharma Sept invests in R&D, and always thrives to achieve elegant and simple new solutions for existing products, as well as developing products for new medical devices in operating rooms.

Pharma Sept is regularly approached by leading Hi-Tech companies seeking solutions for development of their medical devices.

---

**Goals**

**Objectives:** Develop new business in strategic countries.

**Target Businesses:** Distributors, Investors.

**Target Countries:** Austria, North America, the Netherlands, Poland.

---

www.pharmasept.com
Playwork

Category: Healthcare IT, Medical Devices
Sub-Category: Services, Training
Therapeutic Area(s): Rehabilitation
Company Status: Seed, Phase II

Company at a Glance

Playwork is a “Digital-Health” startup company which provides exciting Physiotherapy through seamless integration of IOT technology and Gaming into workout equipment.

By turning the most common PT equipment into data collecting games, Playwork is generating digitally connected workouts that monitor patient’s progress, provide measurable results and speed up recovery.

The company develops digital connectivity and software to support exercise protocols of using various PT equipment such as therapy balls, balance/pressure equipment and range-of-motion therapy tools.

Playwork provides technological “kits” to use while modifying existing equipment. The Company has partnered with distributors to market our “kits” to service providers while charging mostly for the use of our software services with minimal cost for hardware. Our products are designed to support the clinics work flow and insurance reimbursement methods.

Playwork customers are PT facilities and clinics, elderly care establishments, with expected future sales within the private consumers and the general fitness industry.

By offering its products and services, Playwork is continuously committed to improve and develop value based rehabilitation programs and provide the best recovery outcomes for patients.

Technology & Product(s)

Playwork has developed a unique technology that allows us to take the equipment already used today in physiotherapy and transform it into smart, digital, gamified gear.

Playwork’s system provides a game interface integrated within common exercise equipment to; (a) direct specific movements; (b) implements proscribed medical protocols; (c) Measure and record results and outcomes. All Our products are designed to support the clinics work flow and integrate seamlessly within the current daily work method.

Technology: IOT technology which operates using motion detection sensors, installed on common PT equipment.

Gaming: Motion generated interactive gaming integrated with extensive therapeutic knowledge, allowing patients to enjoy fun, goal driven workouts.

Data Driven Rehab: Sessions generate individualized data reports, allowing patients and caregivers increased availability of information while improving their overall efficiency.

The Playwork technology is based on the latest IOT and sensory solutions which enable us to design a unique variety of the most cost-effective technology products and services available today for the PT market.

Goals

Objectives: Improve outcomes of rehabilitative care.

Target Businesses: Rehab/Medical distributors, Healthcare service providers.

Target Countries: EU Market.
Polycart Medical

Category: Medical Devices
Sub-Category: Medical Equipment
Therapeutic Area(s): General Health
Company Status: Initial Revenue

Company at a Glance
Polycart Medical has completed years of research and development and is proud to present POLYAB PL0211. Our production technologies enable the design and manufacture of components of various sizes and designs, tailored to the system that the manufacturers require to provide an antibacterial solution for the patient environment.

Technology & Product(s)
POLYAB PL0211 is an innovative solution featuring a panel made of ABS material that can be converted by thermo-forming technology into a component of the finished product for the patient environment, operating and other rooms where bacterial deposits are substantial, and the risk of infection is high. POLYAB PL0211 contains embedded antibacterial material, unlike other solutions in which antibacterial material coats the inner surfaces, and any groove or scratch exposes the product to renewal of bacterial colonies.

Goals
Objectives: Finding distributors and manufacturers that can produce products from our antibacterial ABS plates.

Target Businesses: Finding distributors and manufacturers from Europe, USA and Canada.

Target Countries: Germany, UK, France, Spain, Italy, Switzerland, Holland, Belgium, Austria, Sweden, Russia, China, Australia, Japan, Singapore, Brazil, USA, Canada and S. Africa.
QinFlow Ltd.

**Category:** Medical Devices  
**Sub-Category:** Medical Equipment  
**Therapeutic Area(s):** EMS – Emergency Medicine Services, Veterinary  
**Company Status:** Initial Revenues

![QinFlow Logo](www.QinFlow.com)

---

**Company at a Glance**

**Background:** trauma and hypothermia is a lethal combination leading to 8x increased mortality within the first 24 hours and longer ICU stay to those who survived. Approximately 20% of trauma patients’ mortality is caused by the hypothermia and not by the injury, and an adult trauma victim with a core temperature less than 32°C is associated with 100% mortality. Trauma is the main cause of death for ages 0–46, with estimated Years Life Lost burden of $671,000,000,000 and $524,000,000,000 per year in the USA and the EU, respectively.

**Company at a Glance:** Quality in Flow (QinFlow) was founded in 2008 by two Israeli Defense Force elite unit veterans who identified the need for rapid, energy efficient, easy-to-use, and portable fluid warmer. Accordingly, since its inception, QinFlow focuses on innovative, life-saving thermoregulation technologies. Leveraging this unique and patented technology, the company's flagship product – the Warrior – provides emergency care professionals across the entire continuum of emergency care with a reliable, simple to operate, and completely portable blood and IV fluid warming device that operates flawlessly in all environmental conditions in order to fight hypothermia and help in saving lives. The Warrior has been adopted by multiple civil and defense premium accounts across the entire continuum of care, including Emergency Medical Services (EMS), Helicopter EMS (HEMS), Search and Rescue (S&R), Emergency Departments (EDs), Operating Rooms (ORs) and Intensive Care Units (ICUs) as their preferred blood and IV fluid warming device. The Warrior’s unique ability to adequately address the distinct needs across the entire continuum of emergency care positions it as a next generation warming device, offering better care at an improved cost of ownership.

**Technology & Product(s)**

The Warrior is based on cutting edge (patented) fluid warming technology. It is a revolutionary portable blood and IV fluid warming device capable of meeting the key performance parameters expected from modern fluid warmers in prehospital and hospital settings, including:

- **Instantaneous warming in all conditions:** warming near-freeze fluids to body temperature within seconds
- **Low resistance to flow:** from KVO to 200 (battery) and 300 (AC) ml/min for the full warming range
- **High battery capacity:** 3–5 liters of warmed fluids per single battery
- **Flexible power sources:** both battery- and AC-operable modes
- **Superb size-performance ratio:** hospital-grade performance in a prehospital chassis
- **Simple to use:** easy to train and troubleshoot
- **Zero maintenance:** no calibration; no spare parts; 5 years between service cycles

**Goals**

**Objectives:** Meet prominent EMS distributors for Russia, Australia, Japan, South Korea, Turkey, Canada. Meet hospital distributors for Germany, France, Spain, Russia, Russia, Australia, Japan, South Korea, Turkey, Canada. Meet commercial and clinical decision makers in the prominent prehospital (EMS, HEMS, etc.) and hospital / health care (ED, Trauma, OR, ICU) organizations. Meet commercial and clinical decision makers in various military services. Gain exposure to relevant participants from investment, media and analysts.

**Target Businesses:** Distributors and end users (buyers, emergency staff, surgeons, anesthetists).

**Target Countries:** Germany, France, Spain, Russia, Russia, Australia, Japan, South Korea, Turkey, Canada.
Salute Rehab

Category: Medical Devices  
Sub-Category: Medical Equipment  
Therapeutic Area(s): Rehabilitation, Pediatrics, Cardiovascular, Neurology and Degenerative Diseases, Orthopedic  
Company Status: Initial Revenues

Company at a Glance

Israeli-based company develops a new technology for rehabilitation following stroke and other neurological impairments as well as orthopedic injuries. The device, Intuitive Neuro-Motion Learning™, design to offer a viable cost-effective solution for post stroke “Home Users” patients, and patients suffering from other Neurological/orthopedic Disorders.

Stroke victims in the United States total approximately 33 million with 780,000 new victims every year, 80% of these patients require rehabilitation. Stroke patients represent the #1 cause for long term rehabilitation needs in the U.S.

Unmet Need Following a stroke, 85% of patients experience upper limb impairment and over 50% of stroke victims in the acute phase are unable to walk. Clinical research shows that stroke patients have the potential to recover limb function by performing repetitive, intense functionally based therapy. Such continual repetition therapy is generally performed manually with a therapist at the clinic or Rehab hospital but without alternative solution for home users.

Salute’s technology (patent pending) designed especially for the “Home user patient”, Salute’s product can cover the entire continuum of rehabilitative care, starting in the inpatient hospital unit, progressing to the outpatient clinic and continuing at the patient’s home.

Technology & Product(s)

Salute’s technology (patent pending) designed especially for the “Home user patient”, it is intuitive and user friendly for neurological disorders and elderly patients. Salute’s device applies an adjustable linear resistive force throughout the full swing of the limb, that linear force increase the proprioceptive feedback to the spinal cord and brain, limb muscles receives an improved signal resulting in a rapid improvement in the limb’s movement.

Salute’s product can cover the entire continuum of rehabilitative care, starting in the inpatient hospital unit, progressing to the outpatient clinic and continuing at the patient’s home. Salute’s product can be fitted to all patient sizes, support both upper and lower extremities. The device clipped onto a wearable belt, it can be clipped on each side for right or left patient injury or for both limb at the same time. The resistive force can be easily adjusted by the patient. A thin cord extends out from the device attaches to a strap harness slipped around the patient leg, when the leg stretches; the cord extends out of the device and exerts a gentle continuous linear resistance which requires a greater effort to stretch the leg, when the leg swings back the cord folds back into the device.

Salute has conducted multiple case studies in Israel, and started a clinical trial with 35 stroke survivors. Preliminary data demonstrate significant improvement.

Goals

Objectives: Strategic Partnership, Distributers , Key Opinion Leaders, Investments.  
Target Businesses: Distributers, Hospitals/rehabilitation clinics, private physiotherapists .  
Target Countries: Worldwide.
Shekel Scales Ltd.

**Category:** Medical Devices, Healthcare IT, Others  
**Sub-Category:** Medical Equipment, Telemedicine, EHR, Hospital Units/Clinics, SW and HW, Industrial use / OEM  
**Therapeutic Area(s):** General Health  
**Company Status:** Revenue Growth

Shekel Scales Ltd., established in 1977, is a worldwide leader in the design and manufacture of electronic scales, advanced weighing systems, and force measurement applications. Since its inception, Shekel has grown steadily to establish its position as a significant innovation leader in the market. Shekel's outstanding combination of sophisticated software and core weighing engineering technology enables the company to offer creative solutions for a wide range of OEM weighing needs. Shekel implements strict quality control management to ensure the highest standards of its products.

Shekel’s Healthweigh® line is a top tier line of digital electronic professional medical scales. The Healthweigh® products yield very high precision results, and are designed to be user friendly. Shekel’s systems were the first in the world to be integrated into warmers and incubators used to sustain premature babies.

Shekel Scales headquarters are situated in Israel. Shekel (Ningbo) Scales factory in China is a wholly owned subsidiary, serves as a production facility for Shekel products. The company also has offices in Europe and in the US with a worldwide distributor base.

**Technology & Product(s)**

Shekel Healthweigh® offers a wide range of high quality digital healthcare scales with unique innovative designs. All scales connect to EHR systems so weighing information can be communicated to the patient’s medical records. Advanced movement compensation technology eliminates involuntary movement made during the weighing process and ensures exact weighing information.

**Healthweigh® Physician Scales** provide a reliable weighing system for medical centers, clinics, hospitals, fitness centers and the home.

**Healthweigh® Special Needs** scales respond to the needs of diverse medical sectors. This range is extremely user oriented, comfortable, easy to use and operate and most importantly – perfectly safe.

**Healthweigh® Neonatal Scale** is ergonomically designed for the newborn and growing baby.

All scales are OIML approved. Shekel is CE certified according to the European Medical Device Directive 93/42/EEC.

**Goals**

**Objectives:** To reach new business partners and distributors.  
**Target Businesses:** Hospitals and Medical Clinics.  
**Target Countries:** Worldwide.
SION MEDICAL Ltd.

Company at a Glance
SION Medical Ltd. is a leading manufacturer of single-use skin cleansing and dermatologic treatment, advanced wound care and surgical solutions for the professional health care sector. The company focuses its attention on the development of skin asepsis solutions, generic creams, ointments and gels for topical dermatologic and wound applications. We currently are located and produce our products in two locations within Israel, Hagoshrim in the North, and Sderot in the South.

Our products are divided in the following product lines:

Cleansing & Care Line offers a wide range of skin antisepsis products used to minimize infections caused by skin pathogens.

Advanced Wound Care Line offers a wide range of advanced, easy to use and affordable wound dressings with a range of unique niche products based on a new impregnated technology.

Surgical Line offers a broad range of devices for the operating theatre such as drapes, packs and staff clothing, customized procedure trays. The Company's dedication to R&D has resulted in its ability to provide products that enhance the performance and delivery of active ingredients and improve personal health. SION Medical targets to develop new innovative products that will influence, support and improve the quality of healthcare through the practice and management of infection control and the application of epidemiology in the healthcare settings. The Company's Quality System is accredited to ISO 9001:2008, EN ISO 13485:2012, ISO 13485:2003 CMDCAS and in compliance with CFR Title 21 Parts 210, 211, 820. Our products bear the CE Mark certification.

Technology & Product(s)
The Company's dedication to R&D has resulted in its ability to provide products that enhance the performance and delivery of active ingredients and improve personal health. SION Medical targets to develop new innovative products that will influence, support and improve the quality of healthcare through the practice and management of infection control and the application of epidemiology in the healthcare settings. The Company's Quality System is accredited to ISO 9001:2008, EN ISO 13485:2012, ISO 13485:2003 CMDCAS and in compliance with CFR Title 21 Parts 210, 211, 820. Our products bear the CE Mark certification.

Our products are divided into several groups:
• Advanced Wound Care
• Wound Care
• Skin Care & Treatment
• Skin Cleansing & Disinfection
• Lubricating Jelly & Refreshing Swabs
• Surgical
• General Hospital Supply

Goals
Objectives: Distribution, Alliances.
Target Businesses: Clinics, Hospitals, Home Care.
Target Countries: Europe, US, Canada, South America, Australia, South Africa.
Synergo® by Medical Enterprises Group

Category: Medical Devices  
Sub-Category: Medical Equipment, MIS – Minimally Invasive System, Drug delivery, Drug Targeting  
Therapeutic Area(s): Urology, Oncology  
Company Status: Regulatory Approval, Revenue Growth

Company at a Glance

Medical Enterprises Group, founded in 1998, develops innovative minimally invasive technologies providing benefits for both patients and healthcare systems.

Our group consists of professional staff and leaders in the field of physics, engineering and clinical experts.

The lead product, Synergo® RITE (Radiofrequency-Induced ThermoChemotherapeutic Effect) offers clinically effective, safe and easy way to deliver the tri-modality local, non-ionizing Radiofrequency radiation, chemotherapy and deep tissue hyperthermia targeted at the tissue by microwave (RF) energy.

Technology & Product(s)

The Synergo® System is a minimally invasive technology used for the treatment of intermediate and high-risk non-muscle invasive bladder cancer. The treatment combines microwave (RF) deep tissue hyperthermia with instillation of chemotherapeutic drug. Application specific software monitors and records treatment parameters during treatment session and provides a user-friendly interface.

A sterile triple lumen, silicone, transurethral Foley catheter is used for the drug intravesical instillation. The catheter is equipped with RF minutarised antenna that radiates the bladder walls, causing phenotypical changes selectively in cancerous cells, creates membrane micro-poring and metabolic changes in these cells to increase the uptake of the drug, enhances drug mobility, and generates heat at the target tissue at the desired, controlled temperature (hyperthermia) which is a synergistic protagonist. 5 thermocouples incorporated inside the catheter monitor bladder wall and urethra temperatures in real time during treatment.

Synergo® treatment is local and performed on an out-patient basis and is successfully given routinely to patients in leading medical centers around the world.

Over 40 published articles and clinical trials have been conducted since 1995 proving its safety and efficacy. The treatment reduces recurrences and the need for repetitive surgical interventions, as well as the need for radical operation of bladder removal, radiotherapy and/or expensive systemic treatments.

About 70% of the patients who have been treated with Synergo® after failing other treatments remain disease-free (no tumor recurrence) for at least 24 months compared to 20–30% when treating patients with other instillations without Synergo®.

Synergo® technology is CE certified since 2001, has been included in the European Urological Guidelines as the only proven device to treat non-muscle invasive bladder cancer and is now in the process of obtaining approval from the U.S. Food and Drug Administration (FDA).

Goals

Objectives: Distributors.

Target Businesses: Medical device companies.

Target Countries: Germany, Austria, UK, Italy, Spain, Poland, Japan, Singapore, S. Korea, S. Africa, Canada, Australia, Brazil.
TavTech

**Category:** Medical Devices  
**Sub-Category:** Medical Equipment, Disposable & Implantable, Endoscope & Accessories, MIS - Minimally Invasive System  
**Therapeutic Area(s):** Dermatology & Aesthetics, Gastrointestinal, Infection Control, Wound Management  
**Company Status:** Revenue Growth

---

**Company at a Glance**

TavTech is an Israeli privately held company, world leader of Jet Technology.

TavTech’s pioneering, patented technology is based on aviation and space science principles and used for medical applications.

---

**Technology & Product(s)**

**TavTech focuses on three main applications:**

1. **Skin rejuvenation and other treatments using transdermal delivery of saline and other agents.** For this application, the JetPeel™ family devices are used. The JetPeel family devices create a unique two-phase jet of micro-droplets consisting of saline solution and gas (air or medical gas) that is accelerated up to 200 m/sec. The jet stream gently and painlessly touches the treated skin to allow for versatile skin treatments and painlessly transdermal delivery of moisture and agents.

2. **Burns and wound management.** For this application, the Jetox™ family devices are used. The Jetox™ family devices painlessly perform cleansing and debridement for burns and other types of wounds, with no mess and at patient’s bed side;

3. **Colonoscopy.** For this application, the Medjet device is used. This is a CO₂ based device allowing for excellent visualization during colonoscopy.

---

**Goals**

**Objectives:** TavTech will remain the world leader in Jet technology in the aesthetic medicine, burns and wounds, and colonoscopy markets. TavTech’s network of distributors is active and well established. TavTech now aims to expend its distribution circles to reach new markets for all products families and to develop co-developments with synergetic technologies.

**Target Businesses:** Potential distributors: Clinics, Beauty/cosmetic chains.

**Target Countries:** Wound management – Japan, Germany, Eastern Europe Aesthetic – US, Latin America, Japan, S.Korea Colonoscopy (endoscopy) – World wide.
Via Surgical Ltd. provides next-generation fixation technology for hernia repair. Realizing that many hernia repairs make use of multiple means for mesh fixation — anchor/helical hernia tacks, manually applied transfascial sutures — Via Surgical has developed a revolutionary fixation technology, FasTouch™ fixation system that provides deployable transfascial suture fixation that is strong and consistent, yet easily and rapidly deployed.

FasTouch, with its lightweight deployable sutures, provides a comprehensive fixation solution for hernia repair. The fixation strength of the sutures stems from the closed locked-loop (CLL) suture concept. The minimal amount of material in the sutures may reduce foreign body response and chronic pain.

Via Surgical was founded in 2012 by Lena and Ofek Levin and Arik Levy, an experienced team that is dedicated to improving and enhancing hernia repair. This same team previously founded and led PolyTouch Medical, developers of an advanced mesh-positioning device for greater accuracy and shorter procedure time.

**Technology & Product(s)**

Via Surgical has developed FasTouch™, a revolutionary fixation technology for surgeons use in hernia repair, one of the most common surgical procedures worldwide. Surgical mesh is affixed over the hernia defect as a bridge. Proper fixation of the mesh is crucial for a successful hernia repair and fixation failure may result in one or more of the following: hernia recurrence, chronic pain, infection and various other complications.

To date, there is no comprehensive mesh fixation solution available and mesh fixation is commonly achieved by applying multiple fixation means: screw-like or anchor-like hernia tacks and in addition, manually applied trans-fascial sutures. The use of these multiple means is associated with significant OR time, elevated post OP pain and complications.

FasTouch’s proprietary design, for the first time, provides physicians a bridge between traditional suturing and stapling or tacking techniques: combining, in one novel solution, the high efficacy associated with suturing and the ease of use and rapidness of tacking devices. FasTouch provides a comprehensive fixation solution in order to increase confidence in eliminating the need to manually suture surgical mesh, cut OR time and improve clinical outcomes due to less pain and infection incidents mostly associated with manual trans-fascial sutures and related skin incisions.

The Via Surgical FasTouch fixation system is a disposable, single-use system designed to deliver fixation suture through and around tissue and the prosthesis during general surgery procedures such as hernia repair. With minimized foreign body material and increased strength, FasTouch’s proprietary designed sutures are delivered as tacks and form a closed “locked” loop (CLL) within soft tissue providing superior fixation that is also easy to use and rapidly applied. The FasTouch fixation system, (pictured below), is designed to be used in either open or laparoscopic hernia repair and can be inserted through a 5mm or larger laparoscopic port sleeve.

**Goals**

**Objectives:** Pre-commercialization of a surgical implant, finding distribution partners.

**Target Businesses:** Hospitals, Distributors and Health Insurance.

**Target Countries:** EU, UK, Asia, Australia, New Zealand.
Viasonix Ltd.

**Category:** Medical Devices  
**Sub-Category:** Medical Equipment, Diagnostic & Monitoring  
**Therapeutic Area(s):** Peripheral Vascular, Neurology and Degenerative Disease, Neuroscience  
**Company Status:** Revenue Growth

**Company at a Glance**

Viasonix is an international leader in providing high-end vascular diagnosis systems. Viasonix 2 main product families include the Falcon product line for peripheral vascular diagnosis (PVD), and the Dolphin product line for advanced Transcranial Doppler (TCD) measurements. Our Falcon product family is already successfully distributed internationally in 5 continents, while the Dolphin is already extremely successful in entering the international markets. Viasonix is ISO 13485 approved, and the Falcon products are cleared for sale by the FDA, CE, Health Canada, TGA, AMAR, TFDA, CFDA, KFDA, and many other national regulatory agencies. The Dolphin has CE approval, as well as several other approvals in process. Viasonix management is extremely experienced and dedicated, and over the past 2 decades has led many products into success in the marketplace.

**Technology & Product(s)**

Viasonix leading product line includes the Falcon peripheral vascular product family, including: Falcon/Pro, Falcon/Quad and Falcon/ABI+. The Falcon is based on the most advanced peripheral vascular diagnosis technology, for diagnosing peripheral vascular diseases. The Falcon is extremely simple to operate, allows complete standard diagnosis protocols, shortens examination time and has an extremely friendly user interface, yet it supports numerous new unique features.

Falcon/Pro is the powerful high-end device, with unmatched capabilities. It is based on Viasonix’s IPU technology, which allows simultaneous support and endless flexibility of 10 pressure channels. In addition, it is the only system offering 10 MHz Doppler support (in addition to standard frequencies) and 5 PPG sensors (for complete and fast Raynaud’s diagnosis). The Falcon/Quad and the Falcon/ ABI+ systems are designed for lower budgets or office operation, yet providing the user with the full range of features that are offered by the advanced Falcon/Pro. The main difference is that these 2 systems support 4 pressure channels. All products support network connectivity, including DICOM, HL7, and GDT.

The Dolphin TCD family is Viasonix’ new product line. The Dolphin product line includes the Dolphin/IQ which is a module that connects to a PC, and the Dolphin/4D system which is a complete stand-alone system with integrated computer and touch-screen display. Based on the vast experience of its’ developers, who developed in the past the world leading Sonara TCD systems, the Dolphin is the most advanced TCD device in the market today. It includes all of the standard known features, as well as support for intraoperative Doppler measurements, analog or digital input/output of external channels, advanced emboli detection, and much much more. The Dolphin’s extremely friendly user interface is un-paralleled.

Viasonix products are regulatory approved in many countries, including FDA (USA), CE (Europe), Health Canada, CFDA (China), TFDA (Taiwan), KFDA (South Korea), AMAR (Israel), TGA (Australia) and many more approvals.

**Goals**

**Objectives:** Viasonix is an international leader in vascular diagnosis and TCD. We aim at increasing our international market share and international distribution network.

**Target Businesses:** The Falcon product family is primarily designed for Vascular and Vascular Surgery Departments in hospitals, vascular laboratories and private clinics. The Dolphin TCD is primarily designed for Neurology and Neuro-surgery departments.

**Target Countries:** Viasonix is already actively selling in numerous countries, and we plan to increase our international distribution network. Please contact us directly for more information.
Virility Medical

Category: Medical Devices
Sub-Category: Disposable & Implantable
Therapeutic Area(s): Urology
Company Status: Clinical trials

Company at a Glance

Background
Virility Medical is a privately held Israeli medical device start-up company, committed to the development of climax control of premature ejaculation. The company is in advanced clinical stage, developing an intimate skin patch with neuromodulation capabilities.

The Need
Premature ejaculation is the most common sexual dysfunction in men. Existing treatments for premature ejaculation rely mostly on pharmacotherapy. Oral therapies include antidepressant drugs, which are mainly prescribed off-label. These drugs have limited efficacy and are associated with systemic side effects, such as headaches and nausea, as well as sexual side effects, such as diminished libido and decreased fertility. Another alternative is topical therapy, i.e. the application of desensitizing agents. This treatment method also offers limited efficacy, along with side effects such as diminished spontaneity and transvaginal absorption resulting in vaginal numbness.
There is still no effective treatment for premature ejaculation.

Market Size
The premature ejaculation market is expected to grow at a Compound Annual Growth Rate (CAGR) of 9.65% and reach $1.95B by 2020. It is estimated that approx. 79 million men are suffering from premature ejaculation in the US and EU, where more than 15 million men are actively seeking medical solutions (based on a study performed by Frost & Sullivan).

Status
Virility has successfully completed two clinical studies, and planning to submit for CE by the end of 2017.

Technology & Product(s)
CaVirility is developing a perineal skin patch for climax control of premature ejaculation. The patch carries an electronic module which delivers low intensity transcutaneous electrical stimulation to the adjacent nerves and muscles.
The patch is flexible and easily conforms to local anatomy. It can be applied even hours before intercourse and allows to maintain sexual spontaneity.
Ejaculation is delayed by electrically inhibiting the typical rhythmic contractions of the muscle responsible for ejaculation.
The patch is fully controlled by a mobile app, allowing the user to precisely determine the intensity of the stimulation.
After climax, as the muscle regains its typical functionality, the patch can be removed and disposed of.
The patch does not use any drugs or needles. It affects only the targeted muscles and only for the duration of intercourse.
The product is planned to be sold Over the Counter.

Goals
Objectives: Allow distributors to touch and feel the product, product exposure and rising awareness, identifying distribution channels and partners.
Target Businesses: Distributors, pharmacies and retail companies.
Target Countries: EU, US, Canada, China, Japan.
VITALERTER

Company at a Glance

VITALERTER has developed an innovative monitoring platform based on smart IoT sensors capable to predict and alert carers before any patient health deterioration and clinical events.

VITALERTER predictive engine empowers nursing home, hospitals and assisted living professionals to improve patient safety and quality care, to reduce dramatically the number of critical events and hospitalizations and consequently allows huge cost savings to public health organizations, insurance companies and families.

Technology & Product(s)

VITALERTER is a non-contact biosensor monitoring platform for long term care and telemedicine. Placed under a mattress or a wheel chair the system uses sophisticated algorithms to accurately monitor vital signs and movements. Therefore, helping long term care facilities enhance patient care and wellness while optimizing operational efficiencies. Vital signs (i.e. heart rate, stroke, HRV and respiratory rate) can be continuously monitored providing early warning of acute clinical events as well as overall health deterioration, infections, anxiety, sleep quality and depression. The system also tracks body motion precluding falls and assists in preventing and managing pressure ulcers and the onset of epileptic episodes with no movement limitation on the patient. Its unique self-calibrating technology uses customized thresholds providing alerts and warning signs optimized per patient. The outcome is diminished false alarm rates, less ICU transfers, better healthcare and cost reduction. A centralized monitoring management platform and dedicated mobile devices minimize the shift overhead workload and encourage shorter response times. Consequently, enhancing patient care and internal efficiencies.

Goals

Objectives: To find well established local distribution partners that work with hospitals and long-term care facilities, Strategic partners such as EMR, Nurse call systems and Medical Beds manufacturers for integrating and implementing our technology.

Target Businesses: Nursing homes and hospitals.

Target Countries: Europe, APAC, USA.
SAVE the DATE

THE 5TH MEDICAL DEVICES & HIT INTERNATIONAL CONFERENCE & EXHIBITION

March 2019 | TEL AVIV

For More Information
MEDINISRAEL@EXPORT.GOV.IL
## Israeli Economic & Trade Global Offices

<table>
<thead>
<tr>
<th>Country</th>
<th>Tel</th>
<th>E-mail</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUSTRALIA - Sydney</td>
<td>+(61.2) 9388-0382</td>
<td><a href="mailto:sydney@israeltrade.gov.il">sydney@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>BELGIUM - Brussels</td>
<td>+(32.2) 373-5534/5</td>
<td><a href="mailto:brussels@israeltrade.gov.il">brussels@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>BRAZIL - Sao Paulo</td>
<td>+(55.11) 3032-3511</td>
<td><a href="mailto:saopaulo@israeltrade.gov.il">saopaulo@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>BRAZIL - Rio</td>
<td>+(55.21) 2546-9886</td>
<td><a href="mailto:rio@israeltrade.gov.il">rio@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>CHILE - Santiago</td>
<td>+(56) 2-2750-0517</td>
<td><a href="mailto:santiago@israeltrade.gov.il">santiago@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>CHINA - Beijing</td>
<td>+(86.10) 8532-0664</td>
<td><a href="mailto:beijing@israeltrade.gov.il">beijing@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>CHINA - Chengdu</td>
<td>+(86) 2868-719-500</td>
<td><a href="mailto:chengdu@israeltrade.gov.il">chengdu@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>CHINA - Guangzhou</td>
<td>+(86. 20)8513-0518/9</td>
<td><a href="mailto:guangzhou@israeltrade.gov.il">guangzhou@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>CHINA - Hong Kong</td>
<td>+(852) 2821-7509</td>
<td><a href="mailto:hongkong@israeltrade.gov.il">hongkong@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>CHINA - Shanghai</td>
<td>+(86.21) 6010-2500</td>
<td><a href="mailto:shanghai@israeltrade.gov.il">shanghai@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>COLOMBIA - Bogota</td>
<td>+(57.1) 327-7514</td>
<td><a href="mailto:bogota@israeltrade.gov.il">bogota@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>FRANCE - Paris</td>
<td>+(33.1) 4076-5560</td>
<td><a href="mailto:paris@israeltrade.gov.il">paris@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>FRANCE - OECD</td>
<td>+(33.1) 4076-5521</td>
<td><a href="mailto:oecd@israeltrade.gov.il">oecd@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>GERMANY - Berlin</td>
<td>+(49.30) 206-4490</td>
<td><a href="mailto:berlin@israeltrade.gov.il">berlin@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>GERMANY - Munich</td>
<td>+(49.89) 5434-86506</td>
<td><a href="mailto:munich@israeltrade.gov.il">munich@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>INDIA - Bangalore</td>
<td>+(91.80) 4936-5320</td>
<td><a href="mailto:Bangalore@israeltrade.gov.il">Bangalore@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>INDIA - New Delhi</td>
<td>+(91.11) 3041-4518</td>
<td><a href="mailto:delhi@israeltrade.gov.il">delhi@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>INDIA - Mumbai</td>
<td>+(91.22) 6160-0500</td>
<td><a href="mailto:mumbai@israeltrade.gov.il">mumbai@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>ITALY - Milano</td>
<td>+(390.2) 7601-5545</td>
<td><a href="mailto:milano@israeltrade.gov.il">milano@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>JAPAN - Tokyo</td>
<td>+(81.3) 3264-0398</td>
<td><a href="mailto:tokyo@israeltrade.gov.il">tokyo@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>KOREA - Seoul</td>
<td>+(82.2) 723-6121/2</td>
<td><a href="mailto:seoul@israeltrade.gov.il">seoul@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>MEXICO - Mexico City</td>
<td>+(52.55) 5201-1511</td>
<td><a href="mailto:mexico@israeltrade.gov.il">mexico@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>NETHERLANDS - Hague</td>
<td>+(31.70) 376-0514</td>
<td><a href="mailto:hague@israeltrade.gov.il">hague@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>PERU - Lima</td>
<td>+(51.1) 9633-9709</td>
<td><a href="mailto:lima@israeltrade.gov.il">lima@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>POLAND - Warsaw</td>
<td>+(48.22) 597-0514</td>
<td><a href="mailto:warsaw@israeltrade.gov.il">warsaw@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>ROMANIA - Bucharest</td>
<td>+(40.21) 302-8508/</td>
<td><a href="mailto:bucharest@israeltrade.gov.il">bucharest@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>RUSSIA - Moscow</td>
<td>+(7.495)7972-737/8/9</td>
<td><a href="mailto:moscow@israeltrade.gov.il">moscow@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>SINGAPORE</td>
<td>+(65) 6834-9220</td>
<td><a href="mailto:singapore@israeltrade.gov.il">singapore@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>SOUTH AFRICA - Johannesburg</td>
<td>+(27.11) 783-9605</td>
<td><a href="mailto:johannesburg@israeltrade.gov.il">johannesburg@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>SPAIN - Madrid</td>
<td>+(34.91) 782-9520/9</td>
<td><a href="mailto:madrid@israeltrade.gov.il">madrid@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>SWITZERLAND - Geneva</td>
<td>+(41.22) 716-0507</td>
<td><a href="mailto:geneva@israeltrade.gov.il">geneva@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>TAIWAN - Taipei</td>
<td>+(886.2) 2757-7221/2</td>
<td><a href="mailto:taipei@israeltrade.gov.il">taipei@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>THAILAND - Bangkok</td>
<td>+(66.2) 204-9241</td>
<td><a href="mailto:bangkok@israeltrade.gov.il">bangkok@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>TURKEY - Istanbul</td>
<td>+(90.212) 317-6513</td>
<td><a href="mailto:istanbul@israeltrade.gov.il">istanbul@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>UNITED KINGDOM - London</td>
<td>+(44.207) 957-9525</td>
<td><a href="mailto:london@israeltrade.gov.il">london@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>UKRAINE - Kiev</td>
<td>+(380.44) 586-1552/3</td>
<td><a href="mailto:kiev@israeltrade.gov.il">kiev@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>U.S.A - Chicago</td>
<td>+(1.312) 332-2160</td>
<td><a href="mailto:chicago@israeltrade.gov.il">chicago@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>U.S.A - Houston</td>
<td>+(1.713) 599-0290</td>
<td><a href="mailto:houston@israeltrade.gov.il">houston@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>U.S.A - San Francisco</td>
<td>+(1.415) 986-2701</td>
<td><a href="mailto:sanfrancisco@israeltrade.gov.il">sanfrancisco@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>U.S.A - New York</td>
<td>+(1.212) 499-5610</td>
<td><a href="mailto:newyork@israeltrade.gov.il">newyork@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>U.S.A - Washington</td>
<td>+(1-202) 364-5695</td>
<td><a href="mailto:washington@israeltrade.gov.il">washington@israeltrade.gov.il</a></td>
</tr>
<tr>
<td>VIETNAM - Hanoi</td>
<td>+(84.43) 843-3140</td>
<td><a href="mailto:vietnam@israeltrade.gov.il">vietnam@israeltrade.gov.il</a></td>
</tr>
</tbody>
</table>
This publication is for informational purposes only. While every effort has been made to ensure that the information is correct, The Israel Export & International Cooperation Institute assumes no responsibility for damages, financial or otherwise, caused by the information herein.

© August 2017 The Israel Export & International Cooperation Institute

Production: IEICI Media & Communication Division | Design: Studio Eti Kalderon